

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Association of platelet to lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025628
Article Type:	Research
Date Submitted by the Author:	02-Aug-2018
Complete List of Authors:	Maimaiti, Ailifeire; First Affiliated Hospital of Xinjiang Medical University Li, Yang; First Affiliated Hospital of Xinjiang Medical University, Wang, Yong-Tao; First Affiliated Hospital of Xinjiang Medical University Yang, Xiang; First Affiliated Hospital of Xinjiang Medical University Li, Xiao-Mei ; First Affiliated Hospital of Xinjiang Medical University Yang, Yi-Ning; First Affiliated Hospital of Xinjiang Medical University, Department of Cardiology Ma, Yi-Tong; First Affiliated Hospital of Xinjiang Medical University, Cardiology
Keywords:	Platelet to lymphocyte ratio, PLR, insufficient myocardial perfusion, acute myocardial infarction, AMI

SCHOLARONE™
Manuscripts

1
2
3 **Association of platelet to lymphocyte count ratio with myocardial reperfusion**
4
5
6 **and major adverse events in patients with acute myocardial infarction**
7

8 **Authors and addresses**
9

10 Ailifeire Maimaiti^{1,2†}, Li Yang^{1,2†}, Yong-Tao Wang^{1,2}, Xiang Yang^{1,2}, Xiao-Mei Li^{1,2}, Yi-Ning
11 Yang^{1,2}, Yi-Tong Ma^{1,2*}
12
13

14
15 * Correspondence author
16

17
18 † Equal contributors
19

20
21 1 Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi,
22
23 China.
24

25
26 2 Xinjiang Key Laboratory of Cardiovascular Disease Research, Urumqi, China.
27

28 **Corresponding authors**
29

30 Prof. Ma Yi-Tong, PhD.
31

32 Department of Cardiology,
33

34
35 First Affiliated Hospital of Xinjiang Medical University,
36

37
38 137 Liyushan South Road,
39

40 Urumqi, 830054, China.
41

42 E-mail: myt-xj@163.com
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT:

Objective: The aim of this study was to investigate the association of platelet to lymphocyte ratio (PLR) with myocardial reperfusion and in-hospital major adverse events (MACE) in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PPCI).

Design: Retrospective cohort study

Setting: Patients and researchers came from two tertiary hospitals

Participants: A total of 445 consecutive AMI patients who underwent PPCI between January 2015 and December 2017 were enrolled. Patients were divided into two groups based on the PLR value: Patients with PLR values in the third tertile was defined as the high PLR group (n=150) and those in the lower 2 tertiles were defined as the low PLR group (n=295). Explicit criteria for inclusion and exclusion were made.

Interventions: No interventions

Primary and secondary outcome measures: Primary outcome measures were defined as cardiovascular death, reinfarction, or target-vessel revascularization. Secondary outcome measures were defined as stroke, non-lethal myocardial infarction, ventricular tachycardia/ventricular fibrillation, in-hospital mortality.

Results: The high PLR group had significantly higher Killip grade (86% vs. 74.6%, P=0.006), Ejection fraction ($34.8\% \pm 6.0$ vs. $37.4\% \pm 7.1$, P=0.006), insufficient myocardial perfusion (23% vs. 13%, P=0.003) and lower postprocedural TIMI flow (17% vs. 10%, P=0.037), lower MBG grade (11% vs. 4%, P=0.007) compared with the low PLR. Multivariate logistic regression analysis indicated that the independent risk factors of impaired myocardial perfusion were

1
2
3 PLR (OR 1.002, 95% CI 1.000-1.005, P=0.056) and BNP (OR 1.001, 95% CI 1.000-1.001,
4
5
6 P=0.015). The high PLR group had significantly higher MACEs (43% vs. 32%, P=0.029).
7

8 **Conclusions:** The study suggested that high PLR was an independent risk factor of impaired
9
10 myocardial reperfusion in AMI patients. Higher PLR is related to advanced heart failure and
11
12 in-hospital MACE in patients with AMI undergoing PPCI.
13
14

15
16 **Trial registration:** No registration
17

18 **Keywords:** Platelet to lymphocyte ratio; PLR; insufficient myocardial perfusion; acute
19
20 myocardial infarction; AMI
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

1. Routine blood parameters were associated with insufficient myocardial perfusion in patients with acute myocardial infarction and adverse events in hospital.
2. PLR is an independent risk factor for insufficient myocardial perfusion in patients with acute myocardial infarction.
3. Sample size of this study was small, and prospective clinical studies with larger samples are needed to confirm the findings.
4. Long-term follow-up of this study was not conducted, and further study was needed to evaluate PLR on long-term prognosis of patients with AMI.

Introduction

Acute myocardial infarction (AMI) is one of the leading causes of death worldwide (1). Emergency coronary intervention (PPCI) is the first choice for AMI patients to recover the blood flow of occlusive coronary artery. Studies have shown that the early reperfusion can effectively reduce the area of myocardial infarction and restore the heart function (2). Although the blood flow of the occlusive vascular restored (TIMI grade is 3 after PPCI), many patients still had insufficient myocardial perfusion (3). This could result in severe myocardial ischemia, malignant arrhythmia, hemodynamic deterioration and other adverse outcomes (4-7). Therefore, it is necessary to find the risk factors that affect myocardial perfusion.

Platelets play a critical role in the formation of acute thrombosis of coronary arteries (8). Increased platelet count was associated with increased infarction area and adverse cardiovascular outcomes in AMI patients (9). Lymphocyte can inhibit

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ischemia-reperfusion injury in AMI, and its counting increasing is associated with inflammatory response decreasing in infarction area (10-11). Lower lymphocyte count was associated with higher mortality in AMI (12). Previous studies have found that PLR can be used as a predictor of long-term mortality, an independent risk factor for non-recurrent flow after PPCI and increased mortality in hospital, and the increase of PLR is positively correlated with the 6-month all-cause mortality in STEMI patients (13-16).

Study on the effect of PLR on myocardial reperfusion and adverse events in patients with acute myocardial infarction have not be done. Thus, this study intends to explore the effects of PLR on myocardial reperfusion and adverse events in patients with acute myocardial infarction and to provide guidance for the improvement of reperfusion therapy.

Material and Methods

Patient and public involvement

This study is a multiple-center, retrospective, cohort study. A total of 445 consecutive AMI patients from two hospitals between January 2015 and December 2017 were respectively reviewed. We analyzed the clinical and angiographic data of consecutive patients diagnosed with acute myocardial infarction. The inclusion criteria as follows: 1. Eligible for the diagnostic criteria of STEMI.; 2. Within 12 hours from the onset of symptoms to PPCI; 3. The results of angiography confirmed that the infarcted blood vessels were left anterior descending (LAD). 4. Complete clinical data collection; The exclusion criteria as follows: 1. Active infection; 2.

1
2
3 History of systemic infectious diseases in two weeks; 3. Malignant tumor; 4.
4
5 Hepatopathy; 5 chronic tuberculosis history; 6. History of heart failure; 7. History of
6
7 PCI; 8. Long-term oral antiplatelet and statin drugs; All patients received 300 mg of
8
9 aspirin and 600 mg clopidogrel or 180 mg of ticagrelor before PPCI. This study protocol
10
11 was reviewed and approved by the Institutional Review Board of the First Affiliated
12
13 Hospital of Xinjiang Medical University and conformed to the principles and
14
15 guidelines of the Declaration of Helsinki. All participants or their close relatives
16
17 provided written informed consent for participation before data collection.
18
19
20
21
22

23 **Clinical data collection**

24
25 Clinical data collection was done by two physicians from electronic medical
26
27 record system independently. Basic information: hospital number, telephone number,
28
29 etc.; Previous medical history and personal history: hypertension and grade, diabetes,
30
31 hyperlipidemia, stroke history, prehospital medication history, smoking history;
32
33 Venous blood samples were drawn before PPCI. Blood test parameters and other
34
35 measurements were determined by standard laboratory methods. Records of blood
36
37 routine before PPCI; biochemical measurements, myocardial enzymes, Brain
38
39 natriuretic peptide (BNP), cardiac ultrasound after PPCI; Two Interventional
40
41 physicians read coronary angiography disc by blind method and record the rate of
42
43 TIMI blood flow and myocardial blush grade (MBG) classification immediately after
44
45 operation; The number of diseased blood vessels, size of the stents, clots, use of
46
47 tirofiban were determined by operation records.
48
49
50
51
52
53

54 **Clinical definitions**

1
2
3
4 The study population was divided into tertiles according to the PLR values at
5
6 admission. High PLR (group 1, N=150) was defined as a value in the third tertile
7
8 (≥ 165.33) and low PLR (group 2, N=295) as a value in the lower two tertiles ($<$
9
10 165.33). Cardiovascular mortality was defined as unexplained sudden death, death
11
12 due to AMI, or malignant arrhythmia. Reinfarction was defined based on universal
13
14 definition of myocardial infarction (MI) guideline [17]. Non-lethal myocardial
15
16 infarction was defined as Type 1 and Type 2 myocardial infarction according to
17
18 guideline [17]. Major adverse cardiac events (MACEs) were defined as
19
20 cardiovascular death, reinfarction, or target-vessel revascularization.
21
22
23
24

25
26 Insufficient myocardial perfusion was defined as a postoperative TIMI stage is
27
28 grade less than 3, or the TIMI stage is grade 3, but the MBG classification is less than
29
30 2 (18).
31
32

33 **Statistical analysis**

34
35 All data were analyzed by SPSS V 24.0 for Windows. Continuous variables are
36
37 presented as mean \pm standard deviation. If the two groups of quantitative data are
38
39 consistent with the normal distribution, then the independent sample t test would be
40
41 performed. If it doesn't fit the normal distribution, then the Wilcoxon's rank test would
42
43 be performed. The comparison between two groups of count data by chi-square test.
44
45 But, if the frequency is lower than 5, Fisher's exact test would be performed. A
46
47 backward stepwise multivariate logistic regression analysis was performed to identify
48
49 independent predictors of insufficient myocardial perfusion. Receiver operating
50
51 characteristic (ROC) analyses was performed to detect the cut off value of PLR in the
52
53
54
55
56
57
58
59
60

prediction of insufficient myocardial perfusion. Statistical significance was defined as $P < 0.05$.

Results

The baseline characteristics of the two groups were presented in table 1. A total of 445 patients (136 from one medical center, 254 from the other) were eligible. The age of patients in high PLR group was higher than patients in low PLR group (62.2 ± 14.1 vs. 59.5 ± 12.2 , $P=0.117$), but no statistical difference was found. High PLR patients were admitted to the hospital with a significantly higher Killip class than low PLR patients (86% vs. 74.6%, $P=0.006$). The left ventricular ejection fraction of patients in the high PLR group was significantly lower than that in the low PLR group ($34.8\% \pm 6.0$ vs. $37.4\% \pm 7.1$, $P=0.006$). Gender, hypertension, diabetes, history of stroke, smoking, hyperlipidemia, and symptom onset to intervention between two groups were not statistically significant different ($P > 0.05$).

Table 1. Baseline clinical characteristics of patients

	Low PLR (n=295)	High PLR (n=150)	<i>P</i> value
Age , years $\bar{x} \pm s$	59.5 \pm 12.2	62.2 \pm 14.1	0.117
Male , n(%)	196 (66.4%)	93 (62%)	0.335
Hypertension , n(%)	160 (54.2%)	80 (53.3%)	0.856
Diabetes , n(%)	80 (27.1%)	33 (22%)	0.241
Stroke , n(%)	20 (6.8%)	13 (8.7%)	0.473
Smoking , n(%)	130 (44.1%)	57 (38%)	0.220
Hyperlipidaemia , n(%)	16 (5.4%)	6 (4%)	0.513

Killip class \geq II , n(%)	220 (74.6%)	129 (86%)	0.006
Ejection fraction, x% \pm s	37.4 \pm 7.1	34.8 \pm 6.0	0.006
Symptom onset to intervention (hours)	7.15 \pm 4.80	7.00 \pm 4.83	0.608
\geq 6	131(44.4%)	66(44.0%)	0.935

The laboratory data of the two groups were presented in Table 2. Preoperative White blood cell count(WBC) (9.0 \pm 3.2 vs. 9.5 \pm 4.1, P=0.044) and red cell distribution width (RDW) (13.2 \pm 2.3 vs. 13.6 \pm 3.1, P=0.026) in the low PLR group was significantly lower. The peak value of BNP (316 \pm 429 pg/ ml VS.614 \pm 610 pg/ml, P < 0.001) and alanine aminotransferase (ALT) (52.1 \pm 60.0 U/Lvs. 64.4 \pm 84.4 U/L, P=0.003) was significantly higher than that in the high PLR group. There was no statistical difference in neutrophils count, monocyte count, hemoglobin, creatinine, total cholesterol (TC), high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), C-reactive protein (CRP), peak cTnT, peak CK-MB.

Table 2. Comparison of laboratory results

	Low PLR (n=295)	High PLR (n=150)	P value
WBC \times 10 ⁹ /L(x \pm s)	9.0 \pm 3.2	9.5 \pm 4.1	0.044
Neutrophil \times 10 ³ /L(x \pm s)	6.5 \pm 6.2	8.1 \pm 6.8	0.171
Monocyte \times 10 ³ /L(x \pm s)	1.0 \pm 4.6	0.5 \pm 0.3	0.167
Hemoglobin (g/L , x \pm s)	135.8 \pm 23.0	129.6 \pm 23.7	0.524
RDW (% , x \pm s)	13.2 \pm 2.3	13.6 \pm 3.1	0.026
ALT (U/L , x \pm s)	52.1 \pm 60.0	64.4 \pm 84.4	0.003
Creatinine (μ mol/L , x \pm s)	78.4 \pm 36.3	76.3 \pm 30.8	0.336
Total cholesterol (μ mol/L , x \pm s)	4.1 \pm 1.1	4.1 \pm 1.0	0.198

HDL-cholesterol (umol/L , x±s)	1.0±0.5	1.1±0.3	0.446
LDL-cholesterol (μmol/L , x±s)	2.5±0.9	2.5±0.8	0.880
CRP (mg/L , x±s)	16.7±26.6	17.8±32.0	0.611
Peak cTnT (U/L , x±s)	4.9±3.8	5.7±4.0	0.236
Peak CK-MB (U/L , x±s)	226±335	242±382	0.498
BNP (pg/ml , x±s)	316±429	614±600	< 0.001

WBC: White blood cell count; RDW: Red cell distribution width; ALT: alanine aminotransferase; HDL: High density lipoprotein; LDL: Low density lipoprotein; CRP: C-reactive protein; CK-MB: Creatine kinase-myocardial band; BNP: Brain natriuretic peptide

The angiographic and procedural characteristics of two groups were presented in Table 3. In the high PLR group the average implanted stent diameter was significantly smaller (2.93 ± 0.47 vs. 2.96 ± 0.40 , $P=0.015$), and thrombus aspiration was relatively higher (64% vs. 52%, $P=0.015$). The patients in high PLR group had significantly lower postprocedural TIMI grade (17% vs. 10%, $P=0.037$) and MBG stage (11% to 4%, $P=0.007$) after PCI. In the high PLR group, the incidence of insufficient myocardial perfusion was significantly increased (23% vs. 13%, $P=0.003$). There was no significant difference in the number of diseased vessels and the number of stent use, the average implanted stent length, the use of tirofiban. The MACE in the high PLR group was significantly higher (43% vs. 32%, $P=0.004$). There was no significant difference non-lethal myocardial infarction, Stroke, In-hospital mortality and Ventricular tachycardia/ventricular fibrillation (Table 4).

Table 3. Angiographic and procedural characteristics of patients

	Low PLR (n=295)	High PLR (n=150)	P value
Number of diseased vessel			
1 , n(%)	103 (35%)	54 (36%)	0.821
≥2 , n(%)	192 (65%)	96 (64%)	
Number of stent use			
1 , n(%)	119 (40%)	66 (44%)	0.459
≥2 , n(%)	176 (60%)	84 (56%)	
Stent length, average (mm , x±s)			
	25.9±6.3	26.4±8.1	0.067
Stent diameter, average (mm , x±s)			
	2.96±0.40	2.93±0.47	0.015
Tirofiban use , n(%)	271 (92%)	135 (90%)	0.511
Thrombus aspiration , n(%)	153 (52%)	96 (64%)	0.015
Postprocedural TIMI grade			
0-2 , n(%)	29(10%)	25(17%)	0.037
3 , n(%)	266(90%)	125(83%)	
MBG grade			
0,1 , n(%)	12(4%)	16(11%)	0.007
2,3 , n(%)	283(96%)	134(89%)	
Insufficient myocardial reperfusion			
	37(13%)	35(23%)	0.003

TIMI: thrombolysis in myocardial infarction; MBG: Myocardial blush grades

Table 4. In-hospital cardiac events and complications

	Low PLR (n=295)	High PLR (n=150)	P value
MACE	95 (32%)	64 (43%)	0.029

Non-lethal myocardial infarction , n(%)	7 (2%)	6 (4%)	0.335
Stroke , n(%)	18 (6%)	11 (7%)	0.619
In-hospital mortality , n(%)	2 (1%)	4 (3%)	0.186
Ventricular tachycardia/ventricular fibrillation , n(%)	69 (23%)	42 (28%)	0.288

MACE: Major adverse cardiac events (cardiovascular death, reinfarction, target–vessel revascularization)

We performed univariate Logistic regression analysis of factors affecting insufficient myocardial perfusion, the result showed that BNP (OR 1.001, 95% CI 1.000 to 1.001 (P = 0.005) and PLR (OR 1.003, 95% CI 1.000 to 1.005 (P = 0.010) can affect the insufficient myocardial perfusion of PPCI patients. We had included all factors to perform multivariate Logistic regression analysis. We found that PLR (OR 1.009, 95% CI 1.004 to 1.009 (P = 0.001) and peak CK - MB (OR 1.002, 95% CI 1.001 to 1.002 (P = 0.067) were independent factors of insufficient myocardial perfusion (Table 5).

Table 5. The independent predictors of insufficient myocardial reperfusion

Variable	Univariate		Multivariate	
	OR (95%CI)	P value	OR (95%CI)	P value
Age	1.013 (0.983-1.033)	0.202	1.008 (0.988-1.029)	0.440
Male gender	1.018 (0.599-1.728)	0.948	1.005 (0.556-1.818)	0.987
Killip class \geq II	1.167 (0.620-2.198)	0.632	0.982 (0.460-2.098)	0.963
Ejection fraction	0.985 (0.948-1.023)	0.436	0.986 (0.947-1.027)	0.488
WBC	1.049 (0.983-1.119)	0.151	1.044 (0.977-1.116)	0.206
RDW	1.016 (0.928-1.112)	0.734	1.008 (0.911-1.115)	0.877
ALT	0.999 (0.995-1.003)	0.576	0.997 (0.993-1.002)	0.268
Stent length	1.007 (0.971-1.044)	0.710	1.005 (0.970-1.042)	0.766
Stent diameter	1.168 (0.643-2.124)	0.610	1.058 (0.580-2.029)	0.799
Thrombus aspiration	1.123 (0.673-1.872)	0.657	1.060 (0.626-1.798)	0.828
BNP	1.001 (1.000-1.001)	0.008	1.001 (1.000-1.001)	0.015
PLR	1.003 (1.000-1.005)	0.021	1.002 (1.000-1.005)	0.056

WBC: White blood cell count; RDW: Red cell distribution width; ALT: alanine aminotransferase; BNP: Brain natriuretic peptide; PLR: Platelet to lymphocyte ratio.

Discussion

Some of the AMI patients still had insufficient myocardial perfusion after receiving PPCI therapy, which would result in poor cardiac function recovery and chronic heart failure (19). Insufficient myocardial perfusion can also increase the long-term mortality of AMI patients (18). Therefore, it is important to find the independent risk factors of insufficient myocardial perfusion, so that we can identify the high-risk AMI patients before PPCI. It can guide us to make strategies for reperfusion therapy before PPCI.

The pathophysiological mechanism of insufficient myocardial reperfusion is about the microvascular blood flow is hindered by microcirculation injury (MVO) or dysfunction (20). The etiological mechanisms: 1) caused by the microthrombus blocking during the intervention producer; 2) endothelial cells protrusion, leukocyte infiltration and myocardial cell edema caused microvascular oppressing; 3) the necrosis of myocardial cells leads to the release of oxygen free radicals and proinflammatory cytokines, which would activate white blood cells and platelets to block the microvessels.

Platelets played a key role in the pathogenesis of AMI through the formation of platelet - fibrin complexes (8). The increasing platelet count was associated with the occurrence of AMI (21). Activating platelets adhered to the vascular endothelial cells and produced inflammatory cytokines, leading to mononuclear cell adhesion and migration, to accelerate the progression of atherosclerotic plaques. These activating adhesion molecules and chemokines promoted the activation of white blood cells and

1
2
3
4 produced reactive oxygen and matrix metalloproteinases to cause plaque instability in
5
6 atherosclerotic plaques (22). Gary et al. found that increasing platelet volume can
7
8 change blood viscosity and promote inflammation (23). Temiz et al. found that
9
10 increasing platelet activity was associated with high incidence of cardiovascular
11
12 events in-hospital (24). These studies indicated that the increasing of platelet count
13
14 was significantly correlated with the occurrence of AMI and poor prognosis.
15
16

17
18 During the pathogenetic process of AMI, lymphocytes entered the
19
20 ischemia-reperfusion injury myocardial tissue and secreted IL-10 to inhibit
21
22 inflammatory response. Meanwhile, the lymphocytes also secreted TF and mmp-1 to
23
24 promote the coagulation reaction (22). Studies have shown a correlation between
25
26 lymphocyte count decreasing and cardiovascular events increasing in patients with
27
28 AMI (10,25). Lymphocyte count decreasing caused by stress can increase the
29
30 incidence of death in AMI patients (26). Therefore, PLR may become a new indicator
31
32 of thrombus formation, inflammatory state, short-term and long-term adverse
33
34 outcomes of patients with AMI.
35
36
37
38
39

40 Basing on the TIMI class after PCI, Abdulkadir et al. divided acute STEMI patients
41
42 into two groups as no-reflow group and reflow group. An analysis of blood routine
43
44 examination before PCI and myocardial reperfusion had presented that the increasing
45
46 of PLR value is an independent risk factor for the prediction of no-reflow in acute
47
48 STEMI patients (27). Burak et al. used the ROC curve analysis to present that a
49
50 PLR>137 predicted adverse events for patients who had undergone PPCI with a
51
52 specificity of 67% and a sensitivity of 63% (28). Alparslan et al. found that PLR is
53
54
55
56
57
58
59
60

1
2
3 significantly associated with the severity and complexity of coronary atherosclerosis
4
5
6 in ACS patients who undergo PPCI. A higher PLR value is an independent predictor
7
8 of an intermediate to high SXscore (15). Preintervention PLR was a strong and
9
10 independent predictor of slow flow/no-reflow after PPCI in patients with acute
11
12 STEMI (29). Murat et al. found that higher PLR is associated with increased risk for
13
14 in-hospital adverse outcomes and 6-month all-cause mortality with STEMI after PPCI
15
16 (16). PLR should be incorporated into the clinical practice of risk stratification for
17
18 patients admitted with STEMI who underwent primary PCI.
19
20
21

22
23 This study found that high PLR was an independent risk factor of insufficient
24
25 myocardial reperfusion in patients with AMI. High PLR were more likely to have
26
27 major adverse events in hospital after PPCI. The results are consistent with the above
28
29 studies. As an independent risk factor, PLR contained two kinds of cell subtype
30
31 information, which has higher predictive value than any single index.
32
33
34

35 This study also found that thrombus aspiration was associated with insufficient
36
37 myocardial reperfusion in patients with AMI. At present, the role of thrombus
38
39 aspiration in PPCI patients was still controversial (30,31). The TASTE test showed
40
41 that thrombus aspiration in PPCI patients did not reduce the total mortality in 30 days
42
43 and 1 year (32). TOTAL study showed that the main endpoints followed up for 180
44
45 days (6.9% vs. 7.0%). $P=0.86$ and 1 year (7.8% vs. 7.8%; $P=0.991$) between the
46
47 thrombus aspiration group and non-thrombus aspiration group were no statistical
48
49 difference (33). In addition, study showed that thrombus aspiration did not improve
50
51 myocardial reperfusion in patients with long-period ischemia, small infarction area
52
53
54
55
56
57
58
59
60

1
2
3 and light thrombosis (34). Hoole et al. observed the changes in microvascular
4
5 resistance (IMR) during PPCI and found that patients with relatively light thrombosis
6
7 were prone to form distal embolization after the thrombus aspiration, which would
8
9 lead to microcirculation injury (35).
10
11

12
13 This study also found that that peak value of BNP were significantly correlate with
14
15 insufficient myocardial reperfusion in those patients with AMI. It is suggested that
16
17 AMI area is large and the cardiac function is poor in these patients. Consistent with
18
19 previous studies, these patients were prone to progression to chronic heart failure and
20
21 increase long-term mortality, which requires close follow-up.
22
23

24 25 **Limitations in this study:**

26
27 1) Sample size of this study was small, and prospective clinical studies with larger
28
29 samples are needed to confirm the findings; 2) this study did not evaluate the decline
30
31 of ECG ST segment after emergency PCI, but former study showed that the ST
32
33 fallback was consistent with the MBG grading results; 3) Long-term follow-up of this
34
35 study was not conducted, and further study was needed to evaluate PLR on long-term
36
37 prognosis of patients with AMI.
38
39
40
41

42 43 **Conclusion**

44
45 PLR was associated with insufficient myocardial perfusion after PPCI in patients
46
47 with AMI. PLR increased AMI patients were more likely to have major
48
49 cardiovascular adverse events in hospital after PCI.
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank the colleagues for their help. we also thank all the patients for their support.

Funding

This work was supported by NSFC grant number 2017E0269.

Conflict of interest

None.

Contributor ship statement

Ailifeire Maimaiti and Li Yang contributed equally to this work. Ailifeire Maimaiti and Yong-Tao Wang were responsible for statistical analysis and write this paper. Li Yang and Xiang Yang provided the database. Xiao-Mei Li and Yi-Ning Yang revised the paper critically for important intellectual content. Yi-Tong Ma was accountable for all aspects of the work and funds collection.

Data sharing statement

The data sets generated and analysed during the current study are available from the corresponding author upon reasonable request.

References

1. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. *Lancet*. 2017;389(10065):197-210.
2. Tra Joppe, van der Wulp Ineke, de Bruijne Martine C et al. Exploring the treatment delay in the care of patients with ST-elevation myocardial infarction undergoing acute percutaneous coronary intervention: a cross-sectional study.[J]. *BMC Health Serv Res*, 2015, 15: 340.
3. Ndrepepa Gjin, Tiroch Klaus, Fusaro Massimiliano et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction.[J]. *J. Am. Coll. Cardiol.*, 2010, 55(21): 2383-9.
4. Haeck JD. Relationship between myocardial reperfusion, infarct size, and mortality. *JACC Cardiovasc Interv*. 2013;6(12):1328.
5. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. *J Am Coll Cardiol*. 2002;39(4):591-7.
6. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. *Circulation*. 2000;101(2):125-30.
7. Hoffmann R, Haager P, Arning J, Christott P, Radke P, Blindt R, et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. *Am J Cardiol*. 2003;92(9):1015-9.

- 1
- 2
- 3
- 4 8. Kapoor JR. Platelet activation and atherothrombosis. *N Engl J Med.* 2008;358(15):1638;
- 5
- 6 author reply -9.
- 7
- 8
- 9 9. Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, Giugliano RP,
- 10
- 11 Antman EM, Braunwald E. Early and long-term clinical outcomes associated with
- 12
- 13 reinfarction following fibrinolytic administration in the Thrombolysis In Myocardial
- 14
- 15 Infarction trials. *J Am Coll Cardiol* 2003;42:7–16.
- 16
- 17
- 18 10. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, et al. Which white
- 19
- 20 blood cell subtypes predict increased cardiovascular risk? *J Am Coll Cardiol.*
- 21
- 22 2005;45(10):1638-43.
- 23
- 24
- 25 11. Guasti Luigina, Dentali Francesco, Castiglioni Luana et al. Neutrophils and clinical
- 26
- 27 outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A
- 28
- 29 systematic review on more than 34,000 subjects.[J]. *Thromb. Haemost.*, 2011, 106(4):
- 30
- 31 591-9.
- 32
- 33
- 34
- 35 12. Bian C, Wu Y, Shi Y, Xu G, Wang J, Xiang M, et al. Predictive value of the relative
- 36
- 37 lymphocyte count in coronary heart disease. *Heart Vessels.* 2010;25(6):469-73.
- 38
- 39
- 40 13. Li Wenzhang, Liu Qianqian, Tang Yin. Platelet to lymphocyte ratio in the prediction of
- 41
- 42 adverse outcomes after acute coronary syndrome: a meta-analysis.[J]. *Sci Rep*, 2017, 7:
- 43
- 44 40426.
- 45
- 46
- 47 14. Azab B, Shah N, Akerman M, McGinn JT, Jr. Value of platelet/lymphocyte ratio as a
- 48
- 49 predictor of all-cause mortality after non-ST-elevation myocardial infarction. *J Thromb*
- 50
- 51 *Thrombolysis.* 2012;34(3):326-34.
- 52
- 53
- 54
- 55 15. Kurtul A, Murat SN, Yarlioglu M, Duran M, Ergun G, Acikgoz SK, et al. Association
- 56
- 57
- 58
- 59
- 60

- of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. *Am J Cardiol.* 2014;114(7):972-8.
16. Ugur M, Gul M, Bozbay M, Cicek G, Uyarel H, Koroglu B, et al. The relationship between platelet to lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction underwent primary coronary intervention. *Blood Coagul Fibrinolysis.* 2014;25(8):806-11.
17. Thygesen Kristian, Alpert Joseph S, White Harvey D et al. Universal definition of myocardial infarction.[J]. *J. Am. Coll. Cardiol.*, 2007, 50(22): 2173-95.
18. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. *Journal of the American College of Cardiology.* 2009;54:281–292.
19. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. *European Heart Journal.* 2016;37:1024–1033.
20. de Waha Suzanne, Patel Manesh R, Granger Christopher B et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials.[J]. *Eur. Heart J.*, 2017, 38(47): 3502-3510.
21. Amraotkar Alok Ravindra, Song David Day, Otero Diana et al. Platelet Count and Mean Platelet Volume at the Time of and After Acute Myocardial Infarction.[J]. *Clin. Appl. Thromb. Hemost.*, 2017, 23(8): 1052-1059.
22. Lindemann S, Krömer B, Seizer P, Gawaz M: Platelets, inflammation and atherosclerosis. *J Thromb Haemost*, 2007; 5(Suppl.1): 203–11
23. Gary T, Pichler M, Belaj K et al: Platelet-to-lymphocyte ratio: a novel marker for critical

- limb ischemia in peripheral arterial occlusive disease patients. *PLoS One*, 2013; 8: 676–88
24. Temiz Ahmet,Gazi Emine,Güngör Ömer et al. Platelet/lymphocyte ratio and risk of in-hospital mortality in patients with ST-elevated myocardial infarction.[J] .*Med. Sci. Monit.*, 2014, 20: 660-5.
25. Frangiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. *Cardiovasc Res*, 2002; 53: 31–412.
26. Ommen SR, Gibbons RJ, Hodge DO, Thomson SP. Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. *Am J Cardiol* 1997;79:812–814.
27. Yildiz Abdulkadir,Yuksel Murat,Oylumlu Mustafa et al. The Utility of the Platelet-Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation Myocardial Infarction.[J] .*Clin. Appl. Thromb. Hemost.*, 2015, 21(3): 223-8.
28. Ayça Burak,Akin Fatih,Okuyan Ertuğrul. Platelet to lymphocyte ratio as a prognostic marker in primary percutaneous coronary intervention.[J] .*Platelets*, 2015, 26(8): 816.
29. Akboga Mehmet Kadri,Canpolat Ugur,Balci Kevser Gulcihan et al. Increased Platelet to Lymphocyte Ratio is Related to Slow Coronary Flow.[J] .*Angiology*, 2016, 67(1): 21-6.
30. Mahmoud Karim D,Zijlstra Felix. Thrombus aspiration in acute myocardial infarction.[J] .*Nat Rev Cardiol*, 2016, 13(7): 418-28.
31. Jolly Sanjit S,James Stefan,Džavík Vladimír et al. Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration.[J] .*Circulation*, 2017, 135(2): 143-152.

- 1
2
3
4 32. Svilaas Tone, Vlaar Pieter J, van der Horst Iwan C et al. Thrombus aspiration during
5
6 primary percutaneous coronary intervention.[J] .N. Engl. J. Med., 2008, 358(6): 557-67.
7
8
9 33. Jolly Sanjit S, Cairns John A, Yusuf Salim et al. Outcomes after thrombus aspiration for
10
11 ST elevation myocardial infarction: 1-year follow-up of the prospective randomised
12
13 TOTAL trial.[J] .Lancet, 2016, 387(10014): 127-35.
14
15
16 34. Vandermolen S, Marciniak M, Byrne J, De Silva K. Thrombus aspiration in acute
17
18 myocardial infarction: concepts, clinical trials, and current guidelines. Coron Artery Dis.
19
20 2016;27(3):233-43.
21
22
23 35. Hoole SP, Jaworski C, Assessment of the index of microcirculatory resistance during
24
25 primary percutaneous coronary intervention comparing manual aspiration catheter
26
27 thrombectomy with balloon angioplasty (IMPACT study): a randomized controlled pilot
28
29 study. Open Heart 2015; 2:e000238.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2-P3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4-P5
Objectives	3	State specific objectives, including any prespecified hypotheses	P5
Methods			
Study design	4	Present key elements of study design early in the paper	P5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P5-P6
		(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	
Participants	6	<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	P5
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
Variables	7	(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	P6
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Data sources/measurement	8*	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P6-P7
		For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	P6
Study size	10	Explain how the study size was arrived at	P6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P6-P7
		(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	
Statistical methods	12	<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	P6
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	

Section/Topic	Item No	Recommendation	Reported on Page No
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P7
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P8-P9
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	P10
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P6
		(b) Report category boundaries when continuous variables were categorized	P11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	P11-P12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P12-P15
Generalisability	21	Discuss the generalisability (external validity) of the study results	P15
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association of platelet to lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-center retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025628.R1
Article Type:	Research
Date Submitted by the Author:	25-Mar-2019
Complete List of Authors:	Maimaiti, Ailifeire; First Affiliated Hospital of Xinjiang Medical University Li, Yang; First Affiliated Hospital of Xinjiang Medical University, Wang, Yong-Tao; First Affiliated Hospital of Xinjiang Medical University Yang, Xiang; First Affiliated Hospital of Xinjiang Medical University Li, Xiao-Mei ; First Affiliated Hospital of Xinjiang Medical University Yang, Yi-Ning; First Affiliated Hospital of Xinjiang Medical University, Department of Cardiology Ma, Yi-Tong; First Affiliated Hospital of Xinjiang Medical University, Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Platelet to lymphocyte ratio, PLR, insufficient myocardial perfusion, acute myocardial infarction, AMI

SCHOLARONE™
Manuscripts

1
2
3
4 **Association of platelet to lymphocyte count ratio with myocardial reperfusion**
5
6 **and major adverse events in patients with acute myocardial infarction: a two-**
7
8
9 **center retrospective cohort study**
10

11 **Authors and addresses**

12
13
14 Ailifeire Maimaiti^{1,2†}, Li Yang^{1,2†}, Yong-Tao Wang^{1,2}, Xiang Yang^{1,2}, Xiao-Mei Li^{1,2}, Yi-Ning

15
16
17 Yang^{1,2}, Yi-Tong Ma^{1,2*}

18
19 * Correspondence author

20
21
22 † Equal contributors

23
24
25 1 Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University,
26
27 Urumqi, China.

28
29
30 2 Xinjiang Key Laboratory of Cardiovascular Disease Research, Urumqi, China.

31
32 **Corresponding authors**

33
34
35 Prof. Ma Yi-Tong, PhD.

36
37
38 Department of Cardiology,

39
40
41 First Affiliated Hospital of Xinjiang Medical University,

42
43
44 137 Liyushan South Road,

45
46
47 Urumqi, 830054, China.

48
49
50 E-mail: myt-xj@163.com

ABSTRACT:

Objective: Insufficient myocardial reperfusion for acute myocardial infarction (AMI) patients during primary percutaneous coronary intervention (PPCI) has a great influence on prognosis.

The aim of this study was to investigate the association of platelet to lymphocyte ratio (PLR) with myocardial reperfusion and in-hospital major adverse events (MACE) in patients with AMI undergoing PPCI.

Design: Retrospective cohort study

Setting: Patients and researchers came from two tertiary hospitals

Participants: A total of 445 consecutive AMI patients who underwent PPCI between January 2015 and December 2017 were enrolled. Patients were divided into two groups based on the PLR value: Patients with PLR values in the third tertile was defined as the high PLR group (n=150) and those in the lower 2 tertiles were defined as the low PLR group (n=295). Explicit criteria for inclusion and exclusion were made.

Interventions: No interventions

Primary and secondary outcome measures: Primary outcome measures were defined as cardiovascular death, reinfarction, or target-vessel revascularization. Secondary outcome measures were defined as stroke, non-lethal myocardial infarction, ventricular tachycardia/ventricular fibrillation, in-hospital mortality.

Results: The high PLR group had insufficient myocardial perfusion (23% vs. 13%, $P=0.003$), postprocedural Thrombolysis in Myocardial Infarction (TIMI) flow grade (0-2) (17% vs. 10%, $P=0.037$), Myocardial blush grades (MBG) grade (0-1) (11% vs. 4%, $P=0.007$), B-type Natriuretic Peptide (BNP) (614 ± 600 vs. 316 ± 429 , $P<0.001$) compared with the low PLR.

1
2
3
4 Multivariate logistic regression analysis indicated that the independent risk factors of impaired
5
6 myocardial perfusion were PLR (OR 1.256, 95% CI 1.003-1.579, P=0.056) and BNP (OR 1.328,
7
8 95% CI 1.056-1.670, P=0.015). The high PLR group had significantly higher MACEs (43% vs.
9
10 32%, P=0.029).
11
12

13
14 **Conclusions:** The study suggested that high PLR and BNP were independent risk factors of
15
16 insufficient myocardial reperfusion in AMI patients. Higher PLR is related to advanced heart
17
18 failure and in-hospital MACEs in patients with AMI undergoing PPCI.
19
20

21
22 **Trial registration:** No registration
23

24
25 **Keywords:** Platelet to lymphocyte ratio; PLR; insufficient myocardial perfusion; acute
26
27 myocardial infarction; AMI
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

1. The first multicenter retrospective cohort study examined the relationship between PLR and myocardial reperfusion.
2. We only included the LAD vascular occlusion in patients with acute myocardial infarction.
3. We grouped the population according to the distribution of PLR values of the participants.
4. Our study population was small and required a larger sample size for prospective clinical studies.
5. The study focused on in-hospital screening and adverse events among participants and lacked long-term follow-up results.

Introduction

Acute myocardial infarction (AMI) is one of the leading causes of death worldwide (1). Emergency coronary intervention (PPCI) is the first choice for AMI patients to restore blood flow. Studies have shown that the early reperfusion can effectively reduce the myocardial infarct (MI) size and restore the heart function (2). Although blood flow of the occluded vascular artery was restored (TIMI grade is 3 after PPCI), many patients still had insufficient myocardial perfusion (3). This could result in severe myocardial ischemia, malignant arrhythmia, hemodynamic deterioration and other adverse outcomes (4-7). It is mainly due to microvascular obstruction (MVO) (8). The main mechanism of microvascular obstruction is ischemia reperfusion (IR) injury of coronary arteries. There are multiple

1
2
3
4 pathophysiological factors (calcium overload, oxidative stress, inflammation, and
5
6 mitochondrial dysfunction), and multiple roles (cardiomyocytes, microvasculature,
7
8 inflammatory cells, and platelets), making it a complex system (9). Therefore, it is
9
10 necessary to find the risk factors that affect myocardial reperfusion.
11
12

13
14 Platelet activation plays a critical role in the formation of acute thrombosis of
15
16 coronary arteries (10). Increased platelet count is associated with the MI size in AMI
17
18 patients and can lead to adverse cardiovascular events (11). Inflammatory response
19
20 plays an important role in the formation of atherosclerotic plaques and myocardial
21
22 ischemia-reperfusion injury. Studies have shown that decreased lymphocyte count
23
24 was associated with increased mortality in AMI patients (12-14). Previous studies
25
26 have found that PLR can be used as a predictor of long-term mortality, an
27
28 independent risk factor for no reflow after PPCI and increased mortality in hospital,
29
30 and the increase of PLR is positively correlated with the 6-month all-cause mortality
31
32 in STEMI patients (15-18).
33
34
35
36
37
38
39

40
41 Studies have showed that the presence of MVO after PPCI as assessed by TIMI
42
43 flow post-PPCI and MBG have all strongly been linked with worse outcomes in AMI
44
45 patients (19-20). The index of microcirculatory resistance (IMR) is a parameter for
46
47 quantifying microcirculatory resistance. There are significant differences in the
48
49 microvascular blood flow between the left anterior descending branch (LAD) and left
50
51 circumflex branch (LCX), as well as the right coronary artery (RC) (21). Although
52
53 previous studies have investigated the relationship between PLR and AMI, they have
54
55 ignored the influence of myocardial ischemic adaptation in different coronary artery
56
57
58
59
60

1
2
3
4 on myocardial reperfusion. To avoid the influence of this variation on the results, we
5
6 only include AMI patients with proximal LAD blocking. Thus, this study intends to
7
8 explore the effects of PLR on myocardial reperfusion and adverse events in AMI
9
10 patients and to provide guidance for the improvement of reperfusion therapy.
11
12

13 **Material and Methods**

14 **Participants**

15
16
17 This study is a multiple-center, retrospective, cohort study. A total of 445
18
19 consecutive AMI patients from two hospitals between January 2015 and December
20
21 2017 were respectively reviewed. We analyzed the clinical and angiographic data of
22
23 consecutive patients diagnosed with acute myocardial infarction. The inclusion
24
25 criteria as follows: 1. Eligible for the diagnostic criteria of STEMI.; 2. Within 12
26
27 hours from the onset of symptoms to PPCI; 3. The results of angiography confirmed
28
29 that the infarcted blood vessels were proximal left anterior descending (LAD). 4.
30
31 Complete clinical data collection; The exclusion criteria as follows: 1. Active
32
33 infection; 2. History of systemic infectious diseases in two weeks; 3. Malignant
34
35 tumor; 4. Hepatopathy; 5 chronic tuberculosis history; 6. History of heart failure; 7.
36
37 History of PCI; 8. Long-term oral antiplatelet and statin drugs; All patients received
38
39 300 mg of aspirin and 600 mg clopidogrel or 180 mg of tigel before PPCI. This study
40
41 protocol was reviewed and approved by the Institutional Review Board of the First
42
43 Affiliated Hospital of Xinjiang Medical University and conformed to the principles
44
45 and guidelines of the Declaration of Helsinki. All participants or their close relatives
46
47 provided written informed consent for participation before data collection.
48
49
50
51
52
53
54
55
56
57
58
59
60

Clinical data collection

Clinical data were collected from the medical records of hospitals by two physicians independently. Basic information: hospital number, telephone number, etc.; Previous medical history and personal history: hypertension and grade, diabetes, hyperlipidemia, stroke history, prehospital medication history, smoking history; Venous blood samples were drawn before PPCI. Blood test parameters and other measurements were determined by standard laboratory methods. Records of blood routine before PPCI; biochemical measurements, myocardial enzymes, BNP, cardiac ultrasound after PPCI; The TIMI and MBG grades of patients were recorded by two interventional doctors in a blind manner; The number of diseased blood vessels, size of the stents, clots, use of tirofiban were determined by operation records.

Clinical definitions

The study population was divided into tertiles according to the PLR values at admission. High PLR (group 1, n=150) was defined as a value in the third tertile (≥ 165.33) and low PLR (group 2, n=295) as a value in the lower two tertiles (< 165.33). Cardiovascular mortality was defined as unexplained sudden death, death due to AMI, or malignant arrhythmia. Reinfarction was defined based on universal definition of MI guideline. Non-lethal myocardial infarction was defined as Type1 and Type2 myocardial infarction according to guideline (22). Major adverse cardiac events (MACEs) were defined as cardiovascular death, reinfarction, or target-vessel revascularization.

Insufficient myocardial perfusion was defined as a postoperative TIMI stage is

1
2
3
4 grade less than 3, or the TIMI stage is grade 3, but the MBG classification is less than
5
6 2 (23).
7

8 9 **Statistical analysis**

10
11 All data were analyzed by SPSS V 24.0 for Windows. Continuous variables are
12 presented as mean \pm standard deviation. If the two groups of quantitative data are
13
14 presented as mean \pm standard deviation. If the two groups of quantitative data are
15 consistent with the normal distribution, then the independent sample t test would be
16
17 performed. if it doesn't fit the normal distribution, then the Wilcoxon's rank test would
18
19 be performed. The comparison between two groups of count data by chi-square test.
20
21 be performed. The comparison between two groups of count data by chi-square test.
22
23 But, if the frequency is lower than 5, Fisher's exact test would be performed. A
24
25 backward stepwise multivariate logistic regression analysis was performed to identify
26
27 independent predictors of insufficient myocardial perfusion. Statistical significance
28
29 was defined as $P < 0.05$.
30
31
32
33
34

35 **Patient and public involvement**

36
37 Participants were not involved in the study design, recruitment, implementation,
38
39 article writing, and data collection. Patients did not incur additional medical burden in
40
41 the study. The results of the study will be disseminated to all patients and medical
42
43 institutions through academic conferences, news reports and health publicity.
44
45
46
47

48 **Results**

49
50 The baseline characteristics of the two groups were presented in table 1. A total of
51
52 445 patients (136 from one medical center, 309 from the other) were eligible. High
53
54 PLR patients were admitted to the hospital with a significantly higher Killip class than
55
56 low PLR patients (86% vs. 74.6%, $P=0.006$). The left ventricular ejection fraction of
57
58
59
60

patients in the high PLR group was significantly lower than that in the low PLR group (34.8%±6.0 vs.37.4%±7.1, P=0.006). Gender, hypertension, diabetes, history of stroke, smoking, hyperlipidemia, and symptom onset to intervention between two groups were not statistically significant different (P > 0.05).

Table 1. Baseline clinical characteristics of patients

	High PLR (n=150)	Low PLR (n=295)	P value
Age , years x±s	62.2±14.1	59.5±12.2	0.117
Male , n(%)	93 (62%)	196 (66.4%)	0.335
Hypertension , n(%)	80 (53.3%)	160 (54.2%)	0.856
Diabetes , n(%)	33 (22%)	80 (27.1%)	0.241
Stroke , n(%)	13 (8.7%)	20 (6.8%)	0.473
Smoking , n(%)	57 (38%)	130 (44.1%)	0.220
Hyperlipidaemia , n(%)	6 (4%)	16 (5.4%)	0.513
Killip class ≥II , n(%)	129 (86%)	220 (74.6%)	0.006
Ejection fraction, x%±s	34.8±6.0	37.4±7.1	0.006
Symptom onset to intervention (hours)	7.00±4.83	7.15±4.80	0.608
≥6	66(44.0%)	131(44.4%)	0.935

The laboratory data of the two groups were presented in Table 2. Preoperative White blood cell count(WBC) (9.5 ± 4.1 vs. 9.0 ± 3.2 , P=0.044) and red cell distribution width (RDW) (13.6 ± 3.1 vs. 13.2 ± 2.3 , P=0.026) in the low PLR group was significantly lower. The peak value of BNP (614 ± 610 pg/ ml VS. 316 ± 429 pg/ml, P < 0.001) and alanine aminotransferase (ALT) (64.4 ± 84.4 U/Lvs. 52.1 ± 60.0 U/L, P=0.003) was

1
2
3
4 significantly higher than that in the high PLR group. There was no statistical difference
5
6 in neutrophils count, monocyte count, hemoglobin, creatinine, total cholesterol (TC),
7
8 high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL),
9
10 C-reactive protein (CRP), peak cTnT, peak CK-MB.
11
12
13
14
15
16
17

18 Table 2. Comparison of laboratory results

	High PLR (n=150)	Low PLR (n=295)	<i>P</i> value
WBC×10 ⁹ /L(x±s)	9.5±4.1	9.0±3.2	0.044
Neutrophil×10 ⁹ /L(x±s)	8.1±6.8	6.5±6.2	0.171
Platelet×10 ⁹ /L(x±s)	264.2±85.9	203.5±74.6	0.006
Lymphocyte×10 ⁹ /L(x±s)	1.15±0.47	2.23±2.41	0.081
Monocyte×10 ⁹ /L(x±s)	0.5±0.3	1.0±4.6	0.167
Hemoglobin (g/L , x±s)	129.6±23.7	135.8±23.0	0.524
RDW (% , x±s)	13.6±3.1	13.2±2.3	0.026
ALT (U/L , x±s)	64.4±84.4	52.1±60.0	0.003
Creatinine (μmol/L , x±s)	76.3±30.8	78.4±36.3	0.336
Total cholesterol (μmol/L , x±s)	4.1±1.0	4.1±1.1	0.198
HDL-cholesterol (umol/L , x±s)	1.1±0.3	1.0±0.5	0.446
LDL-cholesterol (μmol/L , x±s)	2.5±0.8	2.5±0.9	0.880
CRP (mg/L , x±s)	17.8±32.0	16.7±26.6	0.611
Peak cTnT (U/L , x±s)	5.7±4.0	4.9±3.8	0.236
Peak CK-MB (U/L , x±s)	242±382	226±335	0.498

BNP (pg/ml , x±s)	614±600	316±429	< 0.001
-------------------	---------	---------	---------

WBC: White blood cell count; RDW: Red cell distribution width; ALT: alanine aminotransferase; HDL: High density lipoprotein; LDL: Low density lipoprotein; CRP:C-reactive protein; CK-MB: Creatine kinase-myocardial band; BNP: Brain natriuretic peptide

The angiographic and procedural characteristics of two groups were presented in Table 3. In the high PLR group, the average implanted stent diameter was significantly smaller (2.93 ± 0.47 vs. 2.96 ± 0.40 , $P=0.015$), thrombus aspiration was relatively higher (64% vs. 52%, $P=0.015$), and platelet count was higher (264.2 ± 85.9 vs. 203.5 ± 74.6 , $P=0.006$). The patients in high PLR group had significantly lower postprocedural TIMI grade (17% vs. 10%, $P=0.037$) and MBG stage (11% to 4%, $P=0.007$) after PCI. In the high PLR group, the incidence of insufficient myocardial perfusion was significantly increased (23% vs. 13%, $P=0.003$). There was no significant difference in the number of diseased vessels and the number of stent use, the average implanted stent length, the use of tirofiban. The MACEs in the high PLR group was significantly higher (43% vs. 32%, $P=0.004$). There was no significant difference non-lethal myocardial infarction, Stroke, In-hospital mortality and Ventricular tachycardia/ventricular fibrillation (Table 4).

Table 3. Angiographic and procedural characteristics of patients

	High PLR (n=150)	Low PLR (n=295)	<i>P</i> value
Number of diseased vessel			
1 , n(%)	54 (36%)	103 (35%)	0.821
≥2 , n(%)	96 (64%)	192 (65%)	
Number of stent use			
1 , n(%)	66 (44%)	119 (40%)	0.459

≥ 2 , n(%)	84 (56%)	176 (60%)	
Stent length, average			
(mm , x±s)	26.4±8.1	25.9±6.3	0.067
Stent diameter, average			
(mm , x±s)	2.93±0.47	2.96±0.40	0.015
Tirofiban use , n(%)	135 (90%)	271 (92%)	0.511
Thrombus aspiration , n(%)	96 (64%)	153 (52%)	0.015
Postprocedural TIMI grade			
0-2 , n(%)	25(17%)	29(10%)	0.037
3 , n(%)	125(83%)	266(90%)	
MBG grade			
0,1 , n(%)	16(11%)	12(4%)	0.007
2,3 , n(%)	134(89%)	283(96%)	
Insufficient myocardial reperfusion	35(23%)	37(13%)	0.003

TIMI: thrombolysis in myocardial infarction; MBG: Myocardial blush grades

Table4. In-hospital cardiac events and complications

	High PLR (n=150)	Low PLR (n=295)	<i>P</i> value
MACEs	64 (43%)	95 (32%)	0.029
Non-lethal myocardial infarction , n(%)	6 (4%)	7 (2%)	0.335
Stroke , n(%)	11 (7%)	18 (6%)	0.619
In-hospital mortality , n(%)	4 (3%)	2 (1%)	0.186
Ventricular tachycardia/ventricular fibrillation , n(%)	42 (28%)	69 (23%)	0.288

MACE: Major adverse cardiac events (cardiovascular death, reinfarction, target-vessel revascularization)

We performed univariate Logistic regression analysis of factors affecting insufficient myocardial perfusion, the result showed that BNP (OR 1.329, 95% CI 1.057 to 1.672 (P = 0.015) and PLR (OR 1.254, 95% CI 1.001 to 1.571 (P = 0.041) can affect the insufficient myocardial perfusion of PPCI patients. We had included all factors to perform multivariate Logistic regression analysis. We found that PLR (OR 1.256, 95% CI 1.003 to 1.579 (P = 0.001) and BNP (OR 1.328, 95% CI 1.056 to 1.670 (P = 0.015) were independent factors of insufficient myocardial perfusion (Table 5).

Table 5. The independent predictors of insufficient myocardial reperfusion

Variable	Univariate		Multivariate	
	OR (95%CI)	<i>P</i> value	OR (95%CI)	<i>P</i> value
Age	1.013 (0.983-1.033)	0.202	1.008 (0.988-1.028)	0.440
Male gender	1.018 (0.599-1.728)	0.948	1.009 (0.554-1.839)	0.975
Killip class \geq II	1.167 (0.620-2.198)	0.632	0.980 (0.460-2.086)	0.958
Ejection fraction	0.985 (0.948-1.023)	0.436	0.986 (0.947-1.027)	0.488
WBC	1.049 (0.983-1.119)	0.151	1.044 (0.977-1.116)	0.206
Platelet	1.002 (0.999-1.005)	0.037	1.000 (0.996-1.005)	0.872
Lymphocyte	0.766 (0.542-1.082)	0.130	0.906 (0.611-1.344)	0.624
RDW	1.016 (0.928-1.112)	0.734	1.008 (0.911-1.115)	0.878
ALT	0.999 (0.995-1.003)	0.576	0.991 (0.993-1.002)	0.268
Stent length	1.007 (0.971-1.044)	0.710	1.005 (0.969-1.042)	0.793
Stent diameter	1.168 (0.643-2.124)	0.610	1.071 (0.571-2.009)	0.831
Thrombus aspiration	1.123 (0.673-1.872)	0.657	1.046 (0.614-1.780)	0.869
BNP	1.329 (1.057-1.672)	0.015	1.328 (1.056-1.670)	0.015
PLR	1.254 (1.001-1.571)	0.051	1.256 (1.003-1.579)	0.056

WBC: White blood cell count; RDW: Red cell distribution width; ALT: alanine aminotransferase; BNP: Brain natriuretic peptide; PLR: Platelet to lymphocyte ratio.

Discussion

In our study, after modifying the effects of different coronary artery lesions on insufficient myocardial reperfusion, it was found that PLR and BNP were independent risk factors for insufficient myocardial reperfusion after PPCI for AMI patients. In

1
2
3
4 addition, studies have also shown that high PLR is significantly correlated with MACEs,
5
6 Killip grade, EF value, platelet count, RDW, length/diameter of stent implantation, and
7
8 thrombus aspiration of AMI patients.
9

10
11 The pathophysiological mechanism of insufficient myocardial reperfusion is about
12 the microvascular blood flow is hindered by MVO (9,24). The etiological mechanisms:

13
14
15 1) Platelets activation and adhesion that increase cell death and aggregation could
16 effects on myocardial flow (25); 2) Increased endothelial permeability and subsequent
17 recruitment of inflammatory cells into the site of infarction could lead to acute IR injury
18 (26); 3) Mitochondrial dysfunction caused by calcium overload and ROS accumulation
19 can also lead to IR injury (27) PLR as an index contains information on platelet and
20 lymphocyte counts in patients with AMI. It is more significant in predicting insufficient
21 myocardial reperfusion after PPCI in AMI patients than platelet or lymphocyte count.
22
23 Platelets played a key role in the pathogenesis of AMI through the formation of platelet
24 - fibrin complexes (10). The increasing platelet count was associated with the
25 occurrence of AMI (28). Activating platelets adhered to the vascular endothelial cells
26 and produced inflammatory cytokines, leading to mononuclear cell adhesion and
27 migration, to accelerate the progression of atherosclerotic plaques. These activating
28 adhesion molecules and chemokines promoted the activation of white blood cells and
29 produced reactive oxygen and matrix metalloproteinases to cause plaque instability in
30 atherosclerotic plaques (29). Gary et al. found that increasing platelet volume can
31 change blood viscosity and promote inflammation (30). Temiz et al. found that
32 increasing platelet activity was associated with high incidence of cardiovascular events
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 in-hospital (31). These studies indicated that the increasing of platelet count was
5
6 significantly correlated with the occurrence of AMI and poor prognosis.
7
8

9 During the pathogenetic process of AMI, lymphocytes entered the ischemia-
10 reperfusion injury myocardial tissue and secreted IL-10 to inhibit inflammatory
11 response. Meanwhile, the lymphocytes also secreted TF and mmp-1 to promote the
12 coagulation reaction (29). Studies have shown a correlation between lymphocyte
13 count decreasing and cardiovascular events increasing in patients with AMI (12,32).
14 Lymphocyte count decreasing caused by stress can increase the incidence of death in
15 AMI patients (33). Therefore, PLR may become a new indicator of thrombus
16 formation, inflammatory state, short-term and long-term adverse outcomes of patients
17 with AMI.
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Basing on the TIMI class after PCI, Abdulkadir et al. divided acute STEMI patients
33 into two groups as no-reflow group and reflow group. An analysis of blood routine
34 examination before PCI and myocardial reperfusion had presented that the increasing
35 of PLR value is an independent risk factor for the prediction of no-reflow in acute
36 STEMI patients (34). Burak et al. used the ROC curve analysis to present that a
37 PLR>137 predicted adverse events for patients who had undergone PPCI with a
38 specificity of 67% and a sensitivity of 63% (35). Alparslan et al. found that PLR is
39 significantly associated with the severity and complexity of coronary atherosclerosis
40 in ACS patients who undergo PPCI. A higher PLR value is an independent predictor
41 of an intermediate to high SXscore (17). Preintervention PLR was a strong and
42 independent predictor of slow flow/no-reflow after PPCI in patients with acute
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 STEMI (36). Murat et al. found that higher PLR is associated with increased risk for
5
6 in-hospital adverse outcomes and 6-month all-cause mortality with STEMI after PPCI
7
8
9 (18). PLR should be incorporated into the clinical practice of risk stratification for
10
11 patients admitted with STEMI who underwent primary PCI.
12
13

14 Our study found that BNP was an independent risk factor for insufficient
15
16 myocardial reperfusion after PPCI in AMI patients. BNP is a quantitative marker of
17
18 heart failure, which is significantly correlated with left ventricular systolic function
19
20 (37). Besides, during the process of hypoxic, edematous, and necrotic at the
21
22 myocardial infarction site, cardiomyocyte could produce BNP through the
23
24 transcription of NPPB gene in endoplasmic reticulum (38). When occlusion of the
25
26 proximal LAD causes hypoxia and edema of myocardial cells, BNP will be secreted
27
28 in large quantities. Elevated BNP leads to plasma concentration of angiotensin II
29
30 (Ang II) and endothelin-1 (ET-1) by activating renin angiotensin system (RAS) (39).
31
32 This will further aggravate the reperfusion of ischemic myocardium at the infarct site.
33
34 BNP has been shown to be an independent risk factor for ischemia reperfusion injury
35
36 in ST-segment elevation AMI patients (40). Studies have shown that the increased
37
38 secretion of BNP during myocardial ischemia is mainly regulated by the
39
40 PI3K/Akt/p70s6k signaling pathway, which has a protective effect on myocardium
41
42 (41). This change is an adaptation of myocardial cells to ischemia. Therefore, BNP
43
44 level can reflect the severity of myocardial ischemia which is great related to
45
46 insufficient myocardial reperfusion. This study also found that thrombus aspiration
47
48 was associated with insufficient myocardial reperfusion in patients with AMI. At
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 present, the role of thrombus aspiration in PPCI patients was still controversial
5
6 (42,43). The TASTE test showed that thrombus aspiration in PPCI patients did not
7
8 reduce the total mortality in 30 days and 1 year (44). TOTAL study showed that the
9
10 main endpoints followed up for 180 days (6.9% vs. 7.0%). $P=0.86$ and 1 year (7.8%
11
12 vs. 7.8%; $P=0.991$) between the thrombus aspiration group and non-thrombus
13
14 aspiration group were no statistical difference (45). In addition, study showed that
15
16 thrombus aspiration did not improve myocardial reperfusion in patients with long-
17
18 period ischemia, small infarction area and light thrombosis (46). Hoole et al. observed
19
20 the changes in microvascular resistance (IMR) during PPCI and found that patients
21
22 with relatively light thrombosis were prone to form distal embolization after the
23
24 thrombus aspiration, which would lead to microcirculation injury (47).

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Limitations in this study: 1) Sample size of this study was small, and prospective clinical studies with larger samples are needed to confirm the findings; 2) this study did not evaluate the decline of ECG ST segment after emergency PCI, but former study showed that the ST fallback was consistent with the MBG grading results; 3) Long-term follow-up of this study was not conducted, and further study was needed to evaluate PLR on long-term prognosis of patients with AMI.

Conclusion

In a conclusion, our study showed that PLR and BNP on hospital admission could be used as independent risk factors for predicting insufficient myocardial reperfusion after PPCI in AMI patients with proximal LAD occlusion. High PLR is associated with higher MACE incidence during hospitalization. PLR and BNP are convenient and

1
2
3
4 inexpensive detection methods in clinical practice. Clinicians can grade the risk of
5
6 insufficient myocardial reperfusion in AMI patients according to the PLR value.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Acknowledgements

We thank the colleagues for their help. we also thank all the patients for their support.

Funding

This work was supported by NSFC grant number 2017E0269.

Conflict of interest

None.

Contributor ship statement

Ailifeire Maimaiti and Li Yang contributed equally to this work. Ailifeire Maimaiti and Yong-Tao Wang were responsible for statistical analysis and write this paper. Li Yang and Xiang Yang provided the database. Xiao-Mei Li and Yi-Ning Yang revised the paper critically for important intellectual content. Yi-Tong Ma was accountable for all aspects of the work and funds collection.

Data sharing statement

The data sets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

References

1. Reed Grant W, Rossi Jeffrey E, Cannon Christopher P, Acute myocardial infarction. [J] .Lancet, 2017, 389: 197-210.
2. Tra Joppe, van der Wulp Ineke, de Bruijne Martine C et al. Exploring the treatment delay in the care of patients with ST-elevation myocardial infarction undergoing acute percutaneous coronary intervention: a cross-sectional study. [J] .BMC Health Serv Res, 2015, 15: 340.
3. Ndrepepa Gjin, Tiroch Klaus, Fusaro Massimiliano et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. [J] .J. Am. Coll. Cardiol., 2010, 55(21): 2383-9.
4. Haeck Joost D E, Relationship between myocardial reperfusion, infarct size, and mortality. [J] .JACC Cardiovasc Interv, 2013, 6: 1328.
5. Stone Gregg W, Peterson Michael A, Lansky Alexandra J et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. [J] .J. Am. Coll. Cardiol., 2002, 39: 591-7.
6. Gibson C M, Cannon C P, Murphy S A et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. [J] .Circulation, 2000, 101: 125-30.
7. Hoffmann Rainer, Haager Philipp, Arning Jan et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. [J] .Am. J. Cardiol., 2003, 92: 1015-9.
8. Krug A, Du Mesnil de Rochemont , Korb G, Blood supply of the myocardium after

- 1
2
3
4 temporary coronary occlusion.[J] .Circ. Res., 1966, 19: 57-62.
5
6
7 9. Hausenloy Derek J,Botker Hans Erik,Engstrom Thomas et al. Targeting reperfusion
8
9 injury in patients with ST-segment elevation myocardial infarction: trials and
10
11 tribulations.[J] .Eur. Heart J., 2017, 38: 935-941.
12
13
14 10. Davì Giovanni,Patrono Carlo,Platelet activation and atherothrombosis.[J] .N. Engl. J.
15
16 Med., 2007, 357: 2482-94.
17
18
19 11. Gibson C Michael,Karha Juhana,Murphy Sabina A et al. Early and long-term clinical
20
21 outcomes associated with reinfarction following fibrinolytic administration in the
22
23 Thrombolysis in Myocardial Infarction trials.[J] .J. Am. Coll. Cardiol., 2003, 42: 7-16.
24
25
26
27 12. Horne Benjamin D,Anderson Jeffrey L,John Jerry M et al. Which white blood cell
28
29 subtypes predict increased cardiovascular risk?[J] .J. Am. Coll. Cardiol., 2005, 45: 1638-
30
31 43.
32
33
34
35 13. Guasti Luigina,Dentali Francesco,Castiglioni Luana et al. Neutrophils and clinical
36
37 outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A
38
39 systematic review on more than 34,000 subjects.[J] .Thromb. Haemost., 2011, 106(4):
40
41 591-9.
42
43
44
45 14. Bian Chang,Wu Yihua,Shi Yu et al. Predictive value of the relative lymphocyte count in
46
47 coronary heart disease.[J] .Heart Vessels, 2010, 25: 469-73.
48
49
50
51 15. Li Wenzhang,Liu Qianqian,Tang Yin. Platelet to lymphocyte ratio in the prediction of
52
53 adverse outcomes after acute coronary syndrome: a meta-analysis.[J] .Sci Rep, 2017, 7:
54
55 40426.
56
57
58
59 16. Azab Basem,Shah Neeraj,Akerman Meredith et al. Value of platelet/lymphocyte ratio as
60

- 1
2
3
4 a predictor of all-cause mortality after non-ST-elevation myocardial infarction.[J] .J.
5
6 Thromb. Thrombolysis, 2012, 34: 326-34.
7
8
9 17. Kurtul Alparslan,Murat Sani Namik,Yarlioglues Mikail et al. Association of platelet-to-
10
11 lymphocyte ratio with severity and complexity of coronary artery disease in patients with
12
13 acute coronary syndromes.[J] .Am. J. Cardiol., 2014, 114: 972-8.
14
15
16
17 18. Ugur Murat,Gul Mehmet,Bozbay Mehmet et al. The relationship between platelet to
18
19 lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction
20
21 underwent primary coronary intervention.[J] .Blood Coagul. Fibrinolysis, 2014, 25: 806-
22
23 11.
24
25
26
27 19. Morishima I,Sone T,Okumura K et al. Angiographic no-reflow phenomenon as a
28
29 predictor of adverse long-term outcome in patients treated with percutaneous
30
31 transluminal coronary angioplasty for first acute myocardial infarction.[J] .J. Am. Coll.
32
33 Cardiol., 2000, 36: 1202-9.
34
35
36
37 20. Sorajja Paul,Gersh Bernard J,Costantini Costantino et al. Combined prognostic utility of
38
39 ST-segment recovery and myocardial blush after primary percutaneous coronary
40
41 intervention in acute myocardial infarction.[J] .Eur. Heart J., 2005, 26: 667-74.
42
43
44
45 21. Lee Joo Myung,Layland Jamie,Jung Ji-Hyun et al. Integrated physiologic assessment of
46
47 ischemic heart disease in real-world practice using index of microcirculatory resistance
48
49 and fractional flow reserve: insights from the International Index of Microcirculatory
50
51 Resistance Registry.[J] .Circ Cardiovasc Interv, 2015, 8: e002857.
52
53
54
55 22. Thygesen Kristian,Alpert Joseph S,White Harvey D et al. Universal definition of
56
57 myocardial infarction.[J] .J. Am. Coll. Cardiol., 2007, 50(22): 2173-95.
58
59
60

- 1
2
3
4 23. Niccoli Giampaolo,Burzotta Francesco,Galiuto Leonarda et al. Myocardial no-reflow in
5
6 humans.[J] .J. Am. Coll. Cardiol., 2009, 54: 281-92.
7
8
9 24. Niccoli Giampaolo,Scalone Giancarla,Lerman Amir et al. Coronary microvascular
10
11 obstruction in acute myocardial infarction.[J] .Eur. Heart J., 2016, 37: 1024-33.
12
13
14 25. De Waha Suzanne,Patel Manesh R,Granger Christopher B et al. Relationship between
15
16 microvascular obstruction and adverse events following primary percutaneous coronary
17
18 intervention for ST-segment elevation myocardial infarction: an individual patient data
19
20 pooled analysis from seven randomized trials.[J] .Eur. Heart J., 2017, 38(47): 3502-3510.
21
22
23 26. Aurigemma Cristina,Scalone Giancarla,Tomai Fabrizio et al. Persistent enhanced platelet
24
25 activation in patients with acute myocardial infarction and coronary microvascular
26
27 obstruction: clinical implications.[J] .Thromb. Haemost., 2014, 111: 122-30.
28
29
30 27. Hausenloy Derek J,Chilian William,Crea Filippo et al. The coronary circulation in acute
31
32 myocardial ischaemia/reperfusion injury - a target for cardioprotection.[J] .Cardiovasc.
33
34 Res., 2018, undefined: undefined.
35
36
37 28. Javadov Sabzali,Jang Sehwan,Parodi-Rullán Rebecca et al. Mitochondrial permeability
38
39 transition in cardiac ischemia-reperfusion: whether cyclophilin D is a viable target for
40
41 cardioprotection?[J] .Cell. Mol. Life Sci., 2017, 74: 2795-2813.
42
43
44 29. Amraotkar Alok Ravindra,Song David Day,Otero Diana et al. Platelet Count and Mean
45
46 Platelet Volume at the Time of and After Acute Myocardial Infarction.[J] .Clin. Appl.
47
48 Thromb. Hemost., 2017, 23(8): 1052-1059.
49
50
51 30. Lindemann S,Krämer B,Seizer P et al. Platelets, inflammation and atherosclerosis.[J] .J.
52
53 Thromb. Haemost., 2007, null: 203-11.
54
55
56
57
58
59
60

- 1
2
3
4 31. Gary Thomas,Pichler Martin,Belaj Klara et al. Platelet-to-lymphocyte ratio: a novel
5
6 marker for critical limb ischemia in peripheral arterial occlusive disease
7
8
9 patients.[J] .PLoS ONE, 2013, 8: e67688.
10
- 11 32. Temiz Ahmet,Gazi Emine,Güngör Ömer et al. Platelet/lymphocyte ratio and risk of in-
12
13 hospital mortality in patients with ST-elevated myocardial infarction.[J] .Med. Sci.
14
15 Monit., 2014, 20: 660-5.
16
17
- 18 33. Frangogiannis Nikolaos G,Smith C Wayne,Entman Mark L,The inflammatory response
19
20 in myocardial infarction.[J] .Cardiovasc. Res., 2002, 53: 31-47.
21
22
- 23 34. Ommen S R,Gibbons R J,Hodge D O et al. Usefulness of the lymphocyte concentration
24
25 as a prognostic marker in coronary artery disease.[J] .Am. J. Cardiol., 1997, 79: 812-4.
26
27
- 28 35. Yildiz Abdulkadir,Yuksel Murat,Oylumlu Mustafa et al. The Utility of the Platelet-
29
30 Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation
31
32 Myocardial Infarction.[J] .Clin. Appl. Thromb. Hemost., 2015, 21(3): 223-8.
33
34
- 35 36. Ayça Burak,Akin Fatih,Okuyan Ertuğrul. Platelet to lymphocyte ratio as a prognostic
36
37 marker in primary percutaneous coronary intervention.[J] .Platelets, 2015, 26(8): 816.
38
39
- 40 37. Akboga Mehmet Kadri,Canpolat Ugur,Balci Kevser Gulcihan et al. Increased Platelet to
41
42 Lymphocyte Ratio is Related to Slow Coronary Flow.[J] .Angiology, 2016, 67(1): 21-6.
43
44
- 45 38. Abassi Zaid,Karram Tony,Ellaham Samer et al. Implications of the natriuretic
46
47 peptide system in the pathogenesis of heart failure: diagnostic and therapeutic
48
49 importance.[J] .Pharmacol. Ther., 2004, 102: 223-41.
50
51
- 52 39. Hama N,Itoh H,Shirakami G et al. Rapid ventricular induction of brain natriuretic
53
54 peptide gene expression in experimental acute myocardial
55
56
57
58
59
60

- 1
2
3
4 infarction.[J] .Circulation, 1995, 92: 1558-64.
5
6
7 40. Luodonpää M,Vuolteenaho O,Eskelinen S et al. Effects of adrenomedullin on
8
9 hypertrophic responses induced by angiotensin II, endothelin-1 and
10
11 phenylephrine.[J] .Peptides, 2001, 22: 1859-66.
12
13
14 41. Arakawa Kentaro, Himeno Hideo, Kirigaya Jin et al. B-type natriuretic peptide as
15
16 a predictor of ischemia/reperfusion injury immediately after myocardial
17
18 reperfusion in patients with ST-segment elevation acute myocardial
19
20 infarction.[J] .Eur Heart J Acute Cardiovasc Care, 2016, 5: 62-70.
21
22
23 42. Mahmoud Karim D,Zijlstra Felix. Thrombus aspiration in acute myocardial
24
25 infarction.[J] .Nat Rev Cardiol, 2016, 13(7): 418-28.
26
27
28 43. Jolly Sanjit S,James Stefan,Džavík Vladimír et al. Thrombus Aspiration in ST-Segment-
29
30 Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy
31
32 Trialists Collaboration.[J] .Circulation, 2017, 135(2): 143-152.
33
34
35 44. Svilaas Tone,Vlaar Pieter J,van der Horst Iwan C et al. Thrombus aspiration during
36
37 primary percutaneous coronary intervention.[J] .N. Engl. J. Med., 2008, 358(6): 557-67.
38
39
40 45. Jolly Sanjit S,Cairns John A,Yusuf Salim et al. Outcomes after thrombus aspiration for
41
42 ST elevation myocardial infarction: 1-year follow-up of the prospective randomised
43
44 TOTAL trial.[J] .Lancet, 2016, 387(10014): 127-35.
45
46
47 46. Vandermolen Sebastian,Marciniak Maciej,Byrne Jonathan et al. Thrombus aspiration in
48
49 acute myocardial infarction: concepts, clinical trials, and current guidelines.[J] .Coron.
50
51 Artery Dis., 2016, 27: 233-43.
52
53
54 47. Hoole Stephen P,Jaworski Catherine,Brown Adam J et al. Serial assessment of the index
55
56
57
58
59
60

1
2
3
4 of microcirculatory resistance during primary percutaneous coronary intervention
5
6 comparing manual aspiration catheter thrombectomy with balloon angioplasty (IMPACT
7
8
9 study): a randomised controlled pilot study.[J] .Open Heart, 2015, 2: e000238.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE Statement

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2-P3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4-P5
Objectives	3	State specific objectives, including any prespecified hypotheses	P5
Methods			
Study design	4	Present key elements of study design early in the paper	P5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P5-P6
		(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	
Participants	6	<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	P5
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
Variables	7	(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	P6
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Data sources/measurement	8*	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P6-P7
		For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	P6
Study size	10	Explain how the study size was arrived at	P6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P6-P7
		(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	
Statistical methods	12	<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	P6
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	

Section/Topic	Item No	Recommendation	Reported on Page No
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P7
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P8-P9
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	P10
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P6
		(b) Report category boundaries when continuous variables were categorized	P11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	P11-P12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P12-P15
Generalisability	21	Discuss the generalisability (external validity) of the study results	P15
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association of platelet-to-lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-centre retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025628.R2
Article Type:	Research
Date Submitted by the Author:	13-Jul-2019
Complete List of Authors:	Maimaiti, Ailifeire; First Affiliated Hospital of Xinjiang Medical University Li, Yang; First Affiliated Hospital of Xinjiang Medical University, Wang, Yong-Tao; First Affiliated Hospital of Xinjiang Medical University Yang, Xiang; First Affiliated Hospital of Xinjiang Medical University Li, Xiao-Mei ; First Affiliated Hospital of Xinjiang Medical University Yang, Yi-Ning; First Affiliated Hospital of Xinjiang Medical University, Department of Cardiology Ma, Yi-Tong; First Affiliated Hospital of Xinjiang Medical University, Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Platelet to lymphocyte ratio, PLR, insufficient myocardial perfusion, acute myocardial infarction, AMI

SCHOLARONE™
Manuscripts

1
2
3
4 **Association of platelet-to-lymphocyte count ratio with myocardial reperfusion**
5
6 **and major adverse events in patients with acute myocardial infarction: a two-**
7
8 **centre retrospective cohort study**
9
10

11 **Authors and addresses**

12
13
14 Ailifeire Maimaiti^{1,2†}, Li Yang^{1,2†}, Yong-Tao Wang^{1,2}, Xiang Yang^{1,2}, Xiao-Mei Li^{1,2}, Yi-Ning
15
16 Yang^{1,2}, Yi-Tong Ma^{1,2*}

17
18
19 * Correspondence author

20
21
22 † Equal contributors

23
24
25 1 Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University,
26
27 Urumqi, China.

28
29
30 2 Xinjiang Key Laboratory of Cardiovascular Disease Research, Urumqi, China.

31
32 **Corresponding authors**

33
34
35 Prof. Ma Yi-Tong, PhD.

36
37
38 Department of Cardiology,

39
40
41 First Affiliated Hospital of Xinjiang Medical University,

42
43
44 137 Liyushan South Road,

45
46
47 Urumqi, 830054, China.

48
49
50 E-mail: myt-xj@163.com

ABSTRACT:

Objective: Insufficient myocardial reperfusion for acute myocardial infarction (AMI) patients during primary percutaneous coronary intervention (PPCI) has a great influence on prognosis.

The aim of this study was to investigate the association of the platelet-to-lymphocyte ratio (PLR) with myocardial reperfusion and in-hospital major adverse events (MACEs) in patients with AMI undergoing PPCI.

Design: Retrospective cohort study

Setting: Patients and researchers from two tertiary hospitals

Participants: A total of 445 consecutive AMI patients who underwent PPCI between January 2015 and December 2017 were enrolled. Patients were divided into two groups based on the PLR value: patients with PLR values in the third tertile were defined as the high-PLR group (n=150), and those in the lower 2 tertiles were defined as the low-PLR group (n=295).

Explicit criteria for inclusion and exclusion were applied.

Interventions: No interventions

Primary and secondary outcome measures: Primary outcome measures were defined as cardiovascular death, reinfarction, or target vessel revascularization. Secondary outcome measures were defined as stroke, non-lethal myocardial infarction, ventricular tachycardia/ventricular fibrillation, and in-hospital mortality.

Results: The high-PLR group had insufficient myocardial perfusion (23% vs. 13%, P=0.003), greater postprocedural Thrombolysis in Myocardial Infarction (TIMI) flow grade (0-2) (17% vs. 10%, P=0.037), greater myocardial blush grade (MBG) (0-1) (11% vs. 4%, P=0.007), and higher B-type natriuretic peptide (BNP) (614±600 vs. 316±429, P<0.001) compared with the low-PLR

1
2
3
4 group. Multivariate logistic regression analysis indicated that the independent risk factors for
5
6 impaired myocardial perfusion were high PLR (OR 1.256, 95% CI 1.003-1.579, P=0.056) and
7
8 high BNP (OR 1.328, 95% CI 1.056-1.670, P=0.015). The high-PLR group had significantly
9
10 more MACEs (43% vs. 32%, P=0.029).
11
12

13
14 **Conclusions:** This study suggested that high PLR and BNP were independent risk factors for
15
16 insufficient myocardial reperfusion in AMI patients. Higher PLR was related to advanced
17
18 heart failure and in-hospital MACEs in patients with AMI undergoing PPCI.
19
20

21
22 **Trial registration:** No registration
23

24
25 **Keywords:** Platelet to lymphocyte ratio; PLR; insufficient myocardial perfusion; acute
26
27 myocardial infarction; AMI
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

1. The first multicentre retrospective cohort study to examine the relationship between PLR and myocardial reperfusion.
2. We only included patients with LAD vascular occlusion among patients with acute myocardial infarction.
3. We grouped the population according to PLR value.
4. Our study population was small, and a larger sample size will be required for prospective clinical studies.
5. This study focused on in-hospital screening and adverse events among participants and lacked long-term follow-up results.

Introduction

Acute myocardial infarction (AMI) is one of the leading causes of death worldwide (1). Emergency coronary intervention (PPCI) is the first choice for AMI patients to restore blood flow. Studies have shown that early reperfusion can effectively reduce the myocardial infarct (MI) size and restore heart function (2). Although blood flow of the occluded vascular artery is restored (thrombolysis in myocardial infarction (TIMI) grade 3 after PPCI), many patients still have insufficient myocardial perfusion (3). This could result in severe myocardial ischaemia, malignant arrhythmia, haemodynamic deterioration and other adverse outcomes (4-7). The insufficient myocardial perfusion is mainly due to microvascular obstruction (MVO) (8). The main mechanism of microvascular obstruction is ischaemia-reperfusion (IR) injury to coronary arteries. This injury involves multiple pathophysiological factors

1
2
3
4 (calcium overload, oxidative stress, inflammation, and mitochondrial dysfunction)
5
6 and multiple players (cardiomyocytes, microvasculature, inflammatory cells, and
7
8 platelets), making it a complex system (9). Therefore, it is necessary to find the risk
9
10 factors that affect myocardial reperfusion.
11
12

13
14 Platelet activation plays a critical role in the formation of acute thrombosis of
15
16 coronary arteries (10). Increased platelet count is associated with the MI size in AMI
17
18 patients and can lead to adverse cardiovascular events (11). The inflammatory
19
20 response plays an important role in the formation of atherosclerotic plaques and
21
22 myocardial ischaemia-reperfusion injury. Studies have shown that decreased
23
24 lymphocyte count was associated with increased mortality in AMI patients (12-14).
25
26 Previous studies have found that PLR can be used as a predictor of long-term
27
28 mortality and is an independent risk factor for no reflow after PPCI and increased
29
30 mortality in hospital, and the increase in PLR is positively correlated with the 6-
31
32 month all-cause mortality in STEMI patients (15-18).
33
34
35
36
37
38
39

40
41 Studies have shown that the presence of MVO after PPCI as assessed by TIMI flow
42
43 post-PPCI and MBG have all strongly been linked with worse outcomes in AMI
44
45 patients (19-20). The index of microcirculatory resistance (IMR) is a parameter for
46
47 quantifying microcirculatory resistance. There are significant differences in the
48
49 microvascular blood flow between the left anterior descending branch (LAD) and left
50
51 circumflex branch (LCX), as well as the right coronary artery (RC) (21). Although
52
53 previous studies have investigated the relationship between PLR and AMI, they have
54
55 ignored the influence of myocardial ischaemic adaptation in different coronary
56
57
58
59
60

1
2
3
4 arteries on myocardial reperfusion. To avoid the influence of this variation on the
5
6 results, we only included AMI patients with proximal LAD blocking. Thus, this study
7
8 intends to explore the effects of PLR on myocardial reperfusion and adverse events in
9
10 AMI patients and to provide guidance for the improvement of reperfusion therapy.
11
12

13 14 **Material and Methods**

15 16 17 **Participants**

18
19 This study is a multiple-centre retrospective cohort study. A total of 445
20
21 consecutive AMI patients from two hospitals seen between January 2015 and
22
23 December 2017 were reviewed. We analysed the clinical and angiographic data of
24
25 consecutive patients diagnosed with acute myocardial infarction. The inclusion
26
27 criteria were as follows: 1. They were eligible for the diagnostic criteria of STEMI; 2.
28
29 There was ≤ 12 hours from the onset of symptoms to PPCI; 3. The results of
30
31 angiography confirmed that the infarcted blood vessel was the proximal left anterior
32
33 descending (LAD); and 4. Complete clinical data were collected. The exclusion
34
35 criteria were as follows: 1. Active infection; 2. History of systemic infectious diseases
36
37 in the previous two weeks; 3. Malignant tumour; 4. Hepatopathy; 5 Chronic
38
39 tuberculosis history; 6. History of heart failure; 7. History of PCI; 8. Long-term oral
40
41 antiplatelet or statin drugs. All patients received 300 mg of aspirin and 600 mg
42
43 clopidogrel or 180 mg of ticagrelor before PPCI. This study protocol was reviewed
44
45 and approved by the Institutional Review Board of the First Affiliated Hospital of
46
47 Xinjiang Medical University and conformed to the principles and guidelines of the
48
49 Declaration of Helsinki. All participants or their close relatives provided written
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 informed consent for participation before data collection.
5

6 **Clinical data collection**

7
8
9 Clinical data were collected from the medical records of hospitals by two
10
11 physicians independently. Basic information: hospital number, telephone number,
12
13 etc.; previous medical history and personal history: hypertension and grade, diabetes,
14
15 hyperlipidaemia, stroke history, prehospital medication history, and smoking history.
16
17 Venous blood samples were drawn before PPCI. Blood test parameters and other
18
19 measurements were determined by standard laboratory methods. Records of blood
20
21 routine before PPCI: biochemical measurements, myocardial enzymes, and BNP.
22
23 Cardiac ultrasound was done after PPCI. The TIMI and MBG grades of patients were
24
25 recorded by two interventional doctors in a blind manner. The number of diseased
26
27 blood vessels, sizes of the stents, number of clots, and use of tirofiban were
28
29 determined by operation records.
30
31
32
33
34
35
36
37

38 **Clinical definitions**

39
40 The study population was divided into tertiles according to the PLR values at
41
42 admission. High PLR (group 1, n=150) was defined as a value in the third tertile
43
44 (≥ 165.33) and low PLR (group 2, n=295) as a value in the lower two tertiles ($<$
45
46 165.33). Cardiovascular mortality was defined as unexplained sudden death, death
47
48 due to AMI, or malignant arrhythmia. Reinfarction was defined based on the universal
49
50 definition of MI guidelines. Non-lethal myocardial infarction was defined as type 1 or
51
52 type 2 myocardial infarction according to guidelines (22). Major adverse cardiac
53
54 events (MACEs) were defined as cardiovascular death, reinfarction, or target vessel
55
56
57
58
59
60

1
2
3
4 revascularization.

5
6 Insufficient myocardial perfusion was defined as a postoperative TIMI grade less
7
8
9 than 3 or a TIMI grade of 3 but with an MBG classification less than 2 (23).

10 11 **Statistical analysis**

12
13
14 All data were analysed by SPSS V 24.0 for Windows. Continuous variables are
15
16 presented as the mean \pm standard deviation. If two groups of quantitative data were
17
18 consistent with the normal distribution, then they were compared by the independent-
19
20 sample t test . If they did not fit the normal distribution, then they were compared by
21
22 Wilcoxon's rank test. Two groups of count data were compared by the chi-square test
23
24 or, if the frequency was lower than 5, Fisher's exact test. A backward stepwise
25
26 multivariate logistic regression analysis was performed to identify independent
27
28 predictors of insufficient myocardial perfusion. Statistical significance was defined as
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
P < 0.05.

37 38 **Patient and public involvement**

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Participants were not involved in the study design, recruitment, implementation,
article writing, or data collection. Patients did not incur additional medical burden in
the study. The results of the study will be disseminated to all patients and medical
institutions through academic conferences, news reports and health publicity.

51 52 **Results**

53
54
55
56
57
58
59
60
The baseline characteristics of the two groups are presented in table 1. A total of
445 patients (136 from one medical centre, 309 from the other) were eligible. High-
PLR patients were admitted to hospital with a significantly higher Killip class than

low-PLR patients (86% vs. 74.6%, $P=0.006$). The left ventricular ejection fraction of patients in the high-PLR group was significantly lower than that in the low-PLR group ($34.8\% \pm 6.0$ vs. $37.4\% \pm 7.1$, $P=0.006$). Gender, hypertension, diabetes, history of stroke, smoking, hyperlipidaemia, and time from symptom onset to intervention were not significantly different between the two groups ($P > 0.05$).

Table 1. Baseline clinical characteristics of patients

	High PLR (n=150)	Low PLR (n=295)	<i>P</i> value
Age, years $\bar{x} \pm s$	62.2 \pm 14.1	59.5 \pm 12.2	0.117
Male, n(%)	93 (62%)	196 (66.4%)	0.335
Hypertension, n(%)	80 (53.3%)	160 (54.2%)	0.856
Diabetes, n(%)	33 (22%)	80 (27.1%)	0.241
Stroke, n(%)	13 (8.7%)	20 (6.8%)	0.473
Smoking, n(%)	57 (38%)	130 (44.1%)	0.220
Hyperlipidaemia, n(%)	6 (4%)	16 (5.4%)	0.513
Killip class \geq II, n(%)	129 (86%)	220 (74.6%)	0.006
Ejection fraction, $\bar{x} \pm s$	34.8 \pm 6.0	37.4 \pm 7.1	0.006
Symptom onset to intervention (hours)	7.00 \pm 4.83	7.15 \pm 4.80	0.608
≥ 6	66(44.0%)	131(44.4%)	0.935

The laboratory data of the two groups are presented in Table 2. The preoperative white blood cell count (WBC) (9.5 ± 4.1 vs. 9.0 ± 3.2 , $P=0.044$) and red cell distribution width (RDW) (13.6 ± 3.1 vs. 13.2 ± 2.3 , $P=0.026$) in the low-PLR group were significantly lower. The peak values of brain natriuretic peptide (BNP) (614 ± 610 pg/ml vs. 316 ± 429 pg/ml, $P < 0.001$) and alanine aminotransferase (ALT) (64.4 ± 84.4 U/L vs. 52.1 ± 60.0 U/L, $P=0.003$) was significantly higher than in the high-PLR group. There was no significant difference in neutrophil count, monocyte count, haemoglobin, creatinine, total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), C-reactive protein (CRP), peak cTnT, or peak

CK-MB.

Table 2. Comparison of laboratory results

	High PLR (n=150)	Low PLR (n=295)	P value
WBC×10 ⁹ /L (x±s)	9.5±4.1	9.0±3.2	0.044
Neutrophil×10 ⁹ /L (x±s)	8.1±6.8	6.5±6.2	0.171
Platelet×10 ⁹ /L (x±s)	264.2±85.9	203.5±74.6	0.006
Lymphocyte×10 ⁹ /L (x±s)	1.15±0.47	2.23±2.41	0.081
Monocyte×10 ⁹ /L (x±s)	0.5±0.3	1.0±4.6	0.167
Haemoglobin (g/L, x±s)	129.6±23.7	135.8±23.0	0.524
RDW (% , x±s)	13.6±3.1	13.2±2.3	0.026
ALT (U/L, x±s)	64.4±84.4	52.1±60.0	0.003
Creatinine (μmol/L, x±s)	76.3±30.8	78.4±36.3	0.336
Total cholesterol (μmol/L, x±s)	4.1±1.0	4.1±1.1	0.198
HDL-cholesterol (μmol/L, x±s)	1.1±0.3	1.0±0.5	0.446
LDL-cholesterol (μmol/L, x±s)	2.5±0.8	2.5±0.9	0.880
CRP (mg/L, x±s)	17.8±32.0	16.7±26.6	0.611
Peak cTnT (U/L, x±s)	5.7±4.0	4.9±3.8	0.236
Peak CK-MB (U/L, x±s)	242±382	226±335	0.498
BNP (pg/ml, x±s)	614±600	316±429	< 0.001

WBC: white blood cell count; RDW: red cell distribution width; ALT: alanine aminotransferase; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CRP: C-reactive protein; CK-MB: creatine kinase-myocardial band; BNP: brain natriuretic peptide

The angiographic and procedural characteristics of the two groups are presented in Table 3. In the high-PLR group, the average implanted stent diameter was significantly smaller (2.93±0.47 vs. 2.96±0.40, P=0.015), thrombus aspiration was higher (64% vs. 52%, P=0.015), and platelet count was higher (264.2±85.9 vs. 203.5±74.6, P=0.006). The patients in the high-PLR group had significantly lower postprocedural TIMI grade (17% vs. 10%, P=0.037) and MBG stage (11% to 4%, P=0.007) after PCI. In the high-PLR group, the incidence of insufficient myocardial

perfusion was significantly increased (23% vs. 13%, $P=0.003$). There was no significant difference in the number of diseased vessels, the number of stents used, the average implanted stent length, or the use of tirofiban. The MACEs in the high-PLR group were significantly more common (43% vs. 32%, $P=0.004$). There was no significant difference in non-lethal myocardial infarction, stroke, in-hospital mortality or ventricular tachycardia/ventricular fibrillation (Table 4).

Table 3. Angiographic and procedural characteristics of patients

	High PLR (n=150)	Low PLR (n=295)	<i>P</i> value
Number of diseased vessels			
1, n(%)	54 (36%)	103 (35%)	0.821
≥2, n(%)	96 (64%)	192 (65%)	
Number of stent use			
1, n(%)	66 (44%)	119 (40%)	0.459
≥2, n(%)	84 (56%)	176 (60%)	
Stent length, average (mm, $x\pm s$)	26.4±8.1	25.9±6.3	0.067
Stent diameter, average (mm, $x\pm s$)	2.93±0.47	2.96±0.40	0.015
Tirofiban use, n (%)	135 (90%)	271 (92%)	0.511
Thrombus aspiration, n (%)	96 (64%)	153 (52%)	0.015
Postprocedural TIMI grade			
0-2, n (%)	25(17%)	29(10%)	0.037
3, n (%)	125(83%)	266(90%)	
MBG grade			
0,1, n (%)	16(11%)	12(4%)	0.007
2,3, n (%)	134(89%)	283(96%)	
Insufficient myocardial reperfusion	35(23%)	37(13%)	0.003

TIMI: Thrombolysis in Myocardial Infarction; MBG: myocardial blush grade

Table 4. In-hospital cardiac events and complications

	High PLR (n=150)	Low PLR (n=295)	<i>P</i> value
MACEs	64 (43%)	95 (32%)	0.029

Non-lethal myocardial infarction, n (%)	6 (4%)	7 (2%)	0.335
Stroke, n (%)	11 (7%)	18 (6%)	0.619
In-hospital mortality, n (%)	4 (3%)	2 (1%)	0.186
Ventricular tachycardia/ventricular fibrillation, n (%)	42 (28%)	69 (23%)	0.288

MACEs: major adverse cardiac events (cardiovascular death, reinfarction, target vessel revascularization)

We performed univariate logistic regression analysis of factors affecting the sufficiency of myocardial perfusion, and the results showed that high BNP (OR 1.329, 95% CI 1.057 to 1.672 ($P = 0.015$)) and high PLR (OR 1.254, 95% CI 1.001 to 1.571 ($P = 0.041$)) contributed to the insufficient myocardial perfusion of PPCI patients. We included all factors to perform multivariate logistic regression analysis. We found that high PLR (OR 1.256, 95% CI 1.003 to 1.579 ($P = 0.001$)) and high BNP (OR 1.328, 95% CI 1.056 to 1.670 ($P = 0.015$)) were independent risk factors for insufficient myocardial perfusion (Table 5).

Table 5. The independent predictors of insufficient myocardial reperfusion

Variable	Univariate		Multivariate	
	OR (95% CI)	<i>P</i> value	OR (95% CI)	<i>P</i> value
Age	1.013 (0.983-1.033)	0.202	1.008 (0.988-1.028)	0.440
Male sex	1.018 (0.599-1.728)	0.948	1.009 (0.554-1.839)	0.975
Killip class \geq II	1.167 (0.620-2.198)	0.632	0.980 (0.460-2.086)	0.958
Ejection fraction	0.985 (0.948-1.023)	0.436	0.986 (0.947-1.027)	0.488
WBC	1.049 (0.983-1.119)	0.151	1.044 (0.977-1.116)	0.206
Platelet	1.002 (0.999-1.005)	0.037	1.000 (0.996-1.005)	0.872
Lymphocyte	0.766 (0.542-1.082)	0.130	0.906 (0.611-1.344)	0.624
RDW	1.016 (0.928-1.112)	0.734	1.008 (0.911-1.115)	0.878
ALT	0.999 (0.995-1.003)	0.576	0.991 (0.993-1.002)	0.268
Stent length	1.007 (0.971-1.044)	0.710	1.005 (0.969-1.042)	0.793
Stent diameter	1.168 (0.643-2.124)	0.610	1.071 (0.571-2.009)	0.831
Thrombus aspiration	1.123 (0.673-1.872)	0.657	1.046 (0.614-1.780)	0.869
BNP	1.329 (1.057-1.672)	0.015	1.328 (1.056-1.670)	0.015
PLR	1.254 (1.001-1.571)	0.051	1.256 (1.003-1.579)	0.056

WBC: white blood cell count; RDW: red cell distribution width; ALT: alanine aminotransferase; BNP: brain natriuretic peptide; PLR: platelet to lymphocyte ratio.

Discussion

In our study, after controlling for the effects of different coronary artery lesions on insufficient myocardial reperfusion, it was found that high PLR and BNP were independent risk factors for insufficient myocardial reperfusion after PPCI for AMI patients. Earlier studies have shown that high PLR is significantly correlated with MACEs, Killip grade, EF value, platelet count, RDW, length/diameter of stent implantation, and thrombus aspiration in AMI patients.

The pathophysiological mechanism of insufficient myocardial reperfusion is that microvascular blood flow is hindered by MVO (9,24). The aetiological mechanisms are that 1) platelet activation and adhesion, which increase cell death and aggregation, can affect myocardial flow (25); 2) increased endothelial permeability and subsequent recruitment of inflammatory cells into the site of infarction can lead to acute IR injury (26); 3) mitochondrial dysfunction caused by calcium overload and ROS accumulation can also lead to IR injury (27). PLR as an index contains information on platelet and lymphocyte counts in patients with AMI. It is more significant in predicting insufficient myocardial reperfusion after PPCI in AMI patients than platelet or lymphocyte count. Platelets play a key role in the pathogenesis of AMI through the formation of platelet-fibrin complexes (10). Increasing platelet count has been associated with the occurrence of AMI (28). Activating platelets adhere to vascular endothelial cells and produce inflammatory cytokines, leading to mononuclear cell adhesion and migration, accelerating the progression of atherosclerotic plaques. These activating adhesion molecules and chemokines promote the activation of white blood cells and produce

1
2
3
4 reactive oxygen species and matrix metalloproteinases, causing plaque instability in
5
6 atherosclerotic plaques (29). Gary et al. found that increasing platelet volume can
7
8 change blood viscosity and promote inflammation (30). Temiz et al. found that
9
10 increasing platelet activity was associated with a high incidence of cardiovascular
11
12 events in hospital (31). These studies indicated that the increase in platelet count was
13
14 significantly correlated with the occurrence of AMI and poor prognosis.
15
16
17

18
19 During the pathogenetic process of AMI, lymphocytes enter the ischaemia-
20
21 reperfusion-injured myocardial tissue and secrete IL-10 to inhibit the inflammatory
22
23 response. The lymphocytes also secrete TF and mmp-1 to promote the coagulation
24
25 reaction (29). Studies have shown a correlation between decreased lymphocyte count
26
27 and increased frequency of cardiovascular events in patients with AMI (12,32). A
28
29 decrease in lymphocyte count caused by stress can increase the incidence of death in
30
31 AMI patients (33). Therefore, PLR may become a new indicator of thrombus
32
33 formation, inflammatory state, and short-term and long-term adverse outcomes of
34
35 patients with AMI.
36
37
38
39
40
41
42

43 Based on the TIMI class after PCI, Abdulkadir et al. divided acute STEMI patients
44
45 into two groups: no-reflow and reflow. An analysis of routine blood examination
46
47 before PCI and myocardial reperfusion showed that increasing the PLR value was an
48
49 independent risk factor for the prediction of no-reflow in acute STEMI patients (34).
50
51 Burak et al. used ROC curve analysis to show that a PLR>137 predicted adverse
52
53 events for patients who had undergone PPCI, with a specificity of 67% and a
54
55 sensitivity of 63% (35). Alparslan et al. found that PLR was significantly associated
56
57
58
59
60

1
2
3
4 with the severity and complexity of coronary atherosclerosis in ACS patients who
5
6 underwent PPCI. A higher PLR value was an independent predictor of an
7
8 intermediate to high SXscore (17). Preintervention PLR was a strong and independent
9
10 predictor of slow flow/no-reflow after PPCI in patients with acute STEMI (36). Murat
11
12 et al. found that higher PLR was associated with an increased risk for in-hospital
13
14 adverse outcomes and 6-month all-cause mortality with STEMI after PPCI (18). PLR
15
16 should be incorporated into the clinical practice of risk stratification for patients
17
18 admitted with STEMI who undergo primary PCI.
19
20
21
22
23

24
25 Our study found that high BNP was an independent risk factor for insufficient
26
27 myocardial reperfusion after PPCI in AMI patients. BNP is a quantitative marker of
28
29 heart failure that is significantly correlated with left ventricular systolic function (37).
30
31 During the process of hypoxia, oedematosis, and necrosis at the myocardial infarction
32
33 site, cardiomyocytes can produce BNP through the transcription of the NPPB gene in
34
35 the endoplasmic reticulum (38). When occlusion of the proximal LAD causes hypoxia
36
37 and oedema of myocardial cells, BNP will be secreted in large quantities. Elevated
38
39 BNP leads to plasma concentrations of angiotensin II (Ang II) and endothelin-1 (ET-
40
41 1) by activating the renin angiotensin system (RAS) (39). This will further aggravate
42
43 the reperfusion of ischaemic myocardium at the infarct site. BNP has been shown to
44
45 be an independent risk factor for ischaemia-reperfusion injury in ST-segment
46
47 elevation AMI patients (40). Studies have shown that the increased secretion of BNP
48
49 during myocardial ischaemia is mainly regulated by the PI3K/Akt/p70s6k signalling
50
51 pathway, which has a protective effect on the myocardium (41). This change is an
52
53
54
55
56
57
58
59
60

1
2
3
4 adaptation of myocardial cells to ischaemia. Therefore, the BNP level can reflect the
5
6 severity of myocardial ischaemia, which is strongly related to insufficient myocardial
7
8 reperfusion. This study also found that thrombus aspiration was associated with
9
10 insufficient myocardial reperfusion in patients with AMI. At present, the role of
11
12 thrombus aspiration in PPCI patients is still controversial (42,43). The TAPAS study
13
14 showed that thrombus aspiration in PPCI patients did not reduce the total mortality at
15
16 30 days or 1 year (44). The TOTAL study showed that the main endpoints followed
17
18 up for 180 days (6.9% vs. 7.0%). P=0.86) and 1 year (7.8% vs. 7.8%; P=0.991) were
19
20 not significantly different between the thrombus aspiration group and non-thrombus
21
22 aspiration group (45). In addition, a study showed that thrombus aspiration did not
23
24 improve myocardial reperfusion in patients with long-term ischaemia, small infarction
25
26 area and light thrombosis (46). Hoole et al. observed changes in microvascular
27
28 resistance (IMR) during PPCI and found that patients with relatively light thrombosis
29
30 were prone to distal embolization after thrombus aspiration, which would lead to
31
32 microcirculation injury (47).

33
34
35
36
37
38
39
40
41
42
43 Limitations of this study: 1) The sample size of this study was small, and
44
45 prospective clinical studies with larger samples are needed to confirm the findings. 2)
46
47 This study did not evaluate the decline in the ECG ST segment after emergency PCI,
48
49 but a former study showed that the ST fallback was consistent with the MBG grading
50
51 results. 3) Long-term follow-up was not conducted, and further study is needed to
52
53 evaluate the long-term prognosis of patients with AMI.
54
55
56

57 58 59 60 **Conclusion**

1
2
3
4 In conclusion, our study showed that high PLR and BNP on hospital admission could
5
6 be used as independent risk factors for predicting insufficient myocardial reperfusion
7
8 after PPCI in AMI patients with proximal LAD occlusion. High PLR is associated with
9
10 higher MACE incidence during hospitalization. PLR and BNP are convenient and
11
12 inexpensive to detect in clinical practice. Clinicians can grade the risk of insufficient
13
14 myocardial reperfusion in AMI patients according to the PLR value.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank our colleagues for their help. We also thank all the patients for their support.

Funding

This work was supported by NSFC grant number 2017E0269.

Conflict of interest

None declared.

Contributor ship statement

Ailifeire Maimaiti and Li Yang contributed equally to this work. Ailifeire Maimaiti and Yong-Tao Wang were responsible for the statistical analysis and write this paper. Li Yang and Xiang Yang provided the database. Xiao-Mei Li and Yi-Ning Yang critically revised the paper for important intellectual content. Yi-Tong Ma was accountable for all aspects of the work and fund collection.

Data sharing statement

The data sets generated and analysed during the current study are available from the corresponding author upon reasonable request.

References

1. Reed Grant W, Rossi Jeffrey E, Cannon Christopher P, Acute myocardial infarction. [J] .Lancet, 2017, 389: 197-210.
2. Tra Joppe, van der Wulp Ineke, de Bruijne Martine C et al. Exploring the treatment delay in the care of patients with ST-elevation myocardial infarction undergoing acute percutaneous coronary intervention: a cross-sectional study. [J] .BMC Health Serv Res, 2015, 15: 340.
3. Ndrepepa Gjin, Tiroch Klaus, Fusaro Massimiliano et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. [J] .J. Am. Coll. Cardiol., 2010, 55(21): 2383-9.
4. Haeck Joost D E, Relationship between myocardial reperfusion, infarct size, and mortality. [J] .JACC Cardiovasc Interv, 2013, 6: 1328.
5. Stone Gregg W, Peterson Michael A, Lansky Alexandra J et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. [J] .J. Am. Coll. Cardiol., 2002, 39: 591-7.
6. Gibson C M, Cannon C P, Murphy S A et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. [J] .Circulation, 2000, 101: 125-30.
7. Hoffmann Rainer, Haager Philipp, Arning Jan et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. [J] .Am. J. Cardiol., 2003, 92: 1015-9.
8. Krug A, Du Mesnil de Rochemont , Korb G, Blood supply of the myocardium after

- 1
2
3
4 temporary coronary occlusion.[J] .Circ. Res., 1966, 19: 57-62.
5
6
7 9. Hausenloy Derek J,Botker Hans Erik,Engstrom Thomas et al. Targeting reperfusion
8
9 injury in patients with ST-segment elevation myocardial infarction: trials and
10
11 tribulations.[J] .Eur. Heart J., 2017, 38: 935-941.
12
13
14 10. Davì Giovanni,Patrono Carlo,Platelet activation and atherothrombosis.[J] .N. Engl. J.
15
16 Med., 2007, 357: 2482-94.
17
18
19 11. Gibson C Michael,Karha Juhana,Murphy Sabina A et al. Early and long-term clinical
20
21 outcomes associated with reinfarction following fibrinolytic administration in the
22
23 Thrombolysis in Myocardial Infarction trials.[J] .J. Am. Coll. Cardiol., 2003, 42: 7-16.
24
25
26
27 12. Horne Benjamin D,Anderson Jeffrey L,John Jerry M et al. Which white blood cell
28
29 subtypes predict increased cardiovascular risk?[J] .J. Am. Coll. Cardiol., 2005, 45: 1638-
30
31 43.
32
33
34
35 13. Guasti Luigina,Dentali Francesco,Castiglioni Luana et al. Neutrophils and clinical
36
37 outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A
38
39 systematic review on more than 34,000 subjects.[J] .Thromb. Haemost., 2011, 106(4):
40
41 591-9.
42
43
44
45 14. Bian Chang,Wu Yihua,Shi Yu et al. Predictive value of the relative lymphocyte count in
46
47 coronary heart disease.[J] .Heart Vessels, 2010, 25: 469-73.
48
49
50
51 15. Li Wenzhang,Liu Qianqian,Tang Yin. Platelet to lymphocyte ratio in the prediction of
52
53 adverse outcomes after acute coronary syndrome: a meta-analysis.[J] .Sci Rep, 2017, 7:
54
55 40426.
56
57
58
59 16. Azab Basem,Shah Neeraj,Akerman Meredith et al. Value of platelet/lymphocyte ratio as
60

- 1
2
3
4 a predictor of all-cause mortality after non-ST-elevation myocardial infarction.[J] .J.
5
6 Thromb. Thrombolysis, 2012, 34: 326-34.
7
8
9 17. Kurtul Alparslan,Murat Sani Namik,Yarlioglues Mikail et al. Association of platelet-to-
10
11 lymphocyte ratio with severity and complexity of coronary artery disease in patients with
12
13 acute coronary syndromes.[J] .Am. J. Cardiol., 2014, 114: 972-8.
14
15
16
17 18. Ugur Murat,Gul Mehmet,Bozbay Mehmet et al. The relationship between platelet to
18
19 lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction
20
21 underwent primary coronary intervention.[J] .Blood Coagul. Fibrinolysis, 2014, 25: 806-
22
23 11.
24
25
26
27 19. Morishima I,Sone T,Okumura K et al. Angiographic no-reflow phenomenon as a
28
29 predictor of adverse long-term outcome in patients treated with percutaneous
30
31 transluminal coronary angioplasty for first acute myocardial infarction.[J] .J. Am. Coll.
32
33 Cardiol., 2000, 36: 1202-9.
34
35
36
37 20. Sorajja Paul,Gersh Bernard J,Costantini Costantino et al. Combined prognostic utility of
38
39 ST-segment recovery and myocardial blush after primary percutaneous coronary
40
41 intervention in acute myocardial infarction.[J] .Eur. Heart J., 2005, 26: 667-74.
42
43
44
45 21. Lee Joo Myung,Layland Jamie,Jung Ji-Hyun et al. Integrated physiologic assessment of
46
47 ischemic heart disease in real-world practice using index of microcirculatory resistance
48
49 and fractional flow reserve: insights from the International Index of Microcirculatory
50
51 Resistance Registry.[J] .Circ Cardiovasc Interv, 2015, 8: e002857.
52
53
54
55 22. Thygesen Kristian,Alpert Joseph S,White Harvey D et al. Universal definition of
56
57 myocardial infarction.[J] .J. Am. Coll. Cardiol., 2007, 50(22): 2173-95.
58
59
60

- 1
2
3
4 23. Niccoli Giampaolo,Burzotta Francesco,Galiuto Leonarda et al. Myocardial no-reflow in
5
6 humans.[J] .J. Am. Coll. Cardiol., 2009, 54: 281-92.
7
8
9 24. Niccoli Giampaolo,Scalone Giancarla,Lerman Amir et al. Coronary microvascular
10
11 obstruction in acute myocardial infarction.[J] .Eur. Heart J., 2016, 37: 1024-33.
12
13
14 25. De Waha Suzanne,Patel Manesh R,Granger Christopher B et al. Relationship between
15
16 microvascular obstruction and adverse events following primary percutaneous coronary
17
18 intervention for ST-segment elevation myocardial infarction: an individual patient data
19
20 pooled analysis from seven randomized trials.[J] .Eur. Heart J., 2017, 38(47): 3502-3510.
21
22
23 26. Aurigemma Cristina,Scalone Giancarla,Tomai Fabrizio et al. Persistent enhanced platelet
24
25 activation in patients with acute myocardial infarction and coronary microvascular
26
27 obstruction: clinical implications.[J] .Thromb. Haemost., 2014, 111: 122-30.
28
29
30 27. Hausenloy Derek J,Chilian William,Crea Filippo et al. The coronary circulation in acute
31
32 myocardial ischaemia/reperfusion injury - a target for cardioprotection.[J] .Cardiovasc.
33
34 Res., 2018, undefined: undefined.
35
36
37 28. Javadov Sabzali,Jang Sehwan,Parodi-Rullán Rebecca et al. Mitochondrial permeability
38
39 transition in cardiac ischemia-reperfusion: whether cyclophilin D is a viable target for
40
41 cardioprotection?[J] .Cell. Mol. Life Sci., 2017, 74: 2795-2813.
42
43
44 29. Amraotkar Alok Ravindra,Song David Day,Otero Diana et al. Platelet Count and Mean
45
46 Platelet Volume at the Time of and After Acute Myocardial Infarction.[J] .Clin. Appl.
47
48 Thromb. Hemost., 2017, 23(8): 1052-1059.
49
50
51 30. Lindemann S,Krämer B,Seizer P et al. Platelets, inflammation and atherosclerosis.[J] .J.
52
53 Thromb. Haemost., 2007, null: 203-11.
54
55
56
57
58
59
60

- 1
2
3
4 31. Gary Thomas,Pichler Martin,Belaj Klara et al. Platelet-to-lymphocyte ratio: a novel
5
6 marker for critical limb ischemia in peripheral arterial occlusive disease
7
8
9 patients.[J] .PLoS ONE, 2013, 8: e67688.
10
- 11 32. Temiz Ahmet,Gazi Emine,Güngör Ömer et al. Platelet/lymphocyte ratio and risk of in-
12
13 hospital mortality in patients with ST-elevated myocardial infarction.[J] .Med. Sci.
14
15 Monit., 2014, 20: 660-5.
16
- 17 33. Frangogiannis Nikolaos G,Smith C Wayne,Entman Mark L,The inflammatory response
18
19 in myocardial infarction.[J] .Cardiovasc. Res., 2002, 53: 31-47.
20
21
- 22 34. Ommen S R,Gibbons R J,Hodge D O et al. Usefulness of the lymphocyte concentration
23
24 as a prognostic marker in coronary artery disease.[J] .Am. J. Cardiol., 1997, 79: 812-4.
25
26
- 27 35. Yildiz Abdulkadir,Yuksel Murat,Oylumlu Mustafa et al. The Utility of the Platelet-
28
29 Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation
30
31 Myocardial Infarction.[J] .Clin. Appl. Thromb. Hemost., 2015, 21(3): 223-8.
32
33
- 34 36. Ayça Burak,Akin Fatih,Okuyan Ertuğrul. Platelet to lymphocyte ratio as a prognostic
35
36 marker in primary percutaneous coronary intervention.[J] .Platelets, 2015, 26(8): 816.
37
38
- 39 37. Akboga Mehmet Kadri,Canpolat Ugur,Balci Kevser Gulcihan et al. Increased Platelet to
40
41 Lymphocyte Ratio is Related to Slow Coronary Flow.[J] .Angiology, 2016, 67(1): 21-6.
42
43
- 44 38. Abassi Zaid,Karram Tony,Allaham Samer et al. Implications of the natriuretic
45
46 peptide system in the pathogenesis of heart failure: diagnostic and therapeutic
47
48 importance.[J] .Pharmacol. Ther., 2004, 102: 223-41.
49
50
- 51 39. Hama N,Itoh H,Shirakami G et al. Rapid ventricular induction of brain natriuretic
52
53 peptide gene expression in experimental acute myocardial
54
55
56
57
58
59
60

- 1
2
3
4 infarction.[J] .Circulation, 1995, 92: 1558-64.
5
6
7 40. Luodonpää M,Vuolteenaho O,Eskelinen S et al. Effects of adrenomedullin on
8
9 hypertrophic responses induced by angiotensin II, endothelin-1 and
10
11 phenylephrine.[J] .Peptides, 2001, 22: 1859-66.
12
13
14 41. Arakawa Kentaro, Himeno Hideo, Kirigaya Jin et al. B-type natriuretic peptide as
15
16 a predictor of ischemia/reperfusion injury immediately after myocardial
17
18 reperfusion in patients with ST-segment elevation acute myocardial
19
20 infarction.[J] .Eur Heart J Acute Cardiovasc Care, 2016, 5: 62-70.
21
22
23 42. Mahmoud Karim D,Zijlstra Felix. Thrombus aspiration in acute myocardial
24
25 infarction.[J] .Nat Rev Cardiol, 2016, 13(7): 418-28.
26
27
28 43. Jolly Sanjit S,James Stefan,Džavík Vladimír et al. Thrombus Aspiration in ST-Segment-
29
30 Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy
31
32 Trialists Collaboration.[J] .Circulation, 2017, 135(2): 143-152.
33
34
35 44. Svilaas Tone,Vlaar Pieter J,van der Horst Iwan C et al. Thrombus aspiration during
36
37 primary percutaneous coronary intervention.[J] .N. Engl. J. Med., 2008, 358(6): 557-67.
38
39
40 45. Jolly Sanjit S,Cairns John A,Yusuf Salim et al. Outcomes after thrombus aspiration for
41
42 ST elevation myocardial infarction: 1-year follow-up of the prospective randomised
43
44 TOTAL trial.[J] .Lancet, 2016, 387(10014): 127-35.
45
46
47 46. Vandermolen Sebastian,Marciniak Maciej,Byrne Jonathan et al. Thrombus aspiration in
48
49 acute myocardial infarction: concepts, clinical trials, and current guidelines.[J] .Coron.
50
51 Artery Dis., 2016, 27: 233-43.
52
53
54 47. Hoole Stephen P,Jaworski Catherine,Brown Adam J et al. Serial assessment of the index
55
56
57
58
59
60

1
2
3
4 of microcirculatory resistance during primary percutaneous coronary intervention
5
6 comparing manual aspiration catheter thrombectomy with balloon angioplasty (IMPACT
7
8
9 study): a randomised controlled pilot study.[J] .Open Heart, 2015, 2: e000238.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE Statement

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2-P3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4-P5
Objectives	3	State specific objectives, including any prespecified hypotheses	P5
Methods			
Study design	4	Present key elements of study design early in the paper	P5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P5-P6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P5
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
Variables	7	(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	P6
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
		Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P6-P7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P6
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	P6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P6-P7
		(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	
Statistical methods	12	<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	P6
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	

Section/Topic	Item No	Recommendation	Reported on Page No
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P7
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P8-P9
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	P10
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P6
		(b) Report category boundaries when continuous variables were categorized	P11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	P11-P12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P12-P15
Generalisability	21	Discuss the generalisability (external validity) of the study results	P15
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association of platelet-to-lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-centre retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025628.R3
Article Type:	Research
Date Submitted by the Author:	24-Jul-2019
Complete List of Authors:	Maimaiti, Ailifeire; First Affiliated Hospital of Xinjiang Medical University Li, Yang; First Affiliated Hospital of Xinjiang Medical University, Wang, Yong-Tao; First Affiliated Hospital of Xinjiang Medical University Yang, Xiang; First Affiliated Hospital of Xinjiang Medical University Li, Xiao-Mei ; First Affiliated Hospital of Xinjiang Medical University Yang, Yi-Ning; First Affiliated Hospital of Xinjiang Medical University, Department of Cardiology Ma, Yi-Tong; First Affiliated Hospital of Xinjiang Medical University, Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Platelet to lymphocyte ratio, PLR, insufficient myocardial perfusion, acute myocardial infarction, AMI

SCHOLARONE™
Manuscripts

1
2
3
4 **Association of platelet-to-lymphocyte count ratio with myocardial reperfusion**
5
6 **and major adverse events in patients with acute myocardial infarction: a two-**
7
8 **centre retrospective cohort study**
9
10

11 **Authors and addresses**

12
13
14 Ailifeire Maimaiti^{1,2†}, Li Yang^{1,2†}, Yong-Tao Wang^{1,2}, Xiang Yang^{1,2}, Xiao-Mei Li^{1,2}, Yi-Ning
15
16 Yang^{1,2}, Yi-Tong Ma^{1,2*}

17
18
19 * Correspondence author

20
21
22 † Equal contributors

23
24
25 1 Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University,
26
27 Urumqi, China.

28
29
30 2 Xinjiang Key Laboratory of Cardiovascular Disease Research, Urumqi, China.

31
32 **Corresponding authors**

33
34
35 Prof. Ma Yi-Tong, PhD.

36
37
38 Department of Cardiology,

39
40
41 First Affiliated Hospital of Xinjiang Medical University,

42
43
44 137 Liyushan South Road,

45
46
47 Urumqi, 830054, China.

48
49
50 E-mail: myt-xj@163.com

ABSTRACT:

Objective: Insufficient myocardial reperfusion for acute myocardial infarction (AMI) patients during primary percutaneous coronary intervention (PPCI) has a great influence on prognosis.

The aim of this study was to investigate the association of the platelet-to-lymphocyte ratio (PLR) with myocardial reperfusion and in-hospital major adverse events (MACEs) in patients with AMI undergoing PPCI.

Design: Retrospective cohort study

Setting: Patients and researchers from two tertiary hospitals

Participants: A total of 445 consecutive AMI patients who underwent PPCI between January 2015 and December 2017 were enrolled. Patients were divided into two groups based on the PLR value: patients with PLR values in the third tertile were defined as the high-PLR group (n=150), and those in the lower 2 tertiles were defined as the low-PLR group (n=295).

Explicit criteria for inclusion and exclusion were applied.

Interventions: No interventions

Primary and secondary outcome measures: Primary outcome measures were defined as cardiovascular death, reinfarction, or target vessel revascularization. Secondary outcome measures were defined as stroke, non-lethal myocardial infarction, ventricular tachycardia/ventricular fibrillation, and in-hospital mortality.

Results: The high-PLR group had insufficient myocardial perfusion (23% vs. 13%, P=0.003), greater postprocedural Thrombolysis in Myocardial Infarction (TIMI) flow grade (0-2) (17% vs. 10%, P=0.037), greater myocardial blush grade (MBG) (0-1) (11% vs. 4%, P=0.007), and higher B-type natriuretic peptide (BNP) (614±600 vs. 316±429, P<0.001) compared with the low-PLR

1
2
3
4 group. Multivariate logistic regression analysis indicated that the independent risk factors for
5
6 impaired myocardial perfusion were high PLR (OR 1.256, 95% CI 1.003-1.579, P=0.056) and
7
8 high BNP (OR 1.328, 95% CI 1.056-1.670, P=0.015). The high-PLR group had significantly
9
10 more MACEs (43% vs. 32%, P=0.029).
11
12

13
14 **Conclusions:** This study suggested that high PLR and BNP were independent risk factors for
15
16 insufficient myocardial reperfusion in AMI patients. Higher PLR was related to advanced
17
18 heart failure and in-hospital MACEs in patients with AMI undergoing PPCI.
19
20

21
22 **Trial registration:** No registration
23

24
25 **Keywords:** Platelet to lymphocyte ratio; PLR; insufficient myocardial perfusion; acute
26
27 myocardial infarction; AMI
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

1. The first multicentre retrospective cohort study to examine the relationship between PLR and myocardial reperfusion.
2. We only included patients with LAD vascular occlusion among patients with acute myocardial infarction.
3. We grouped the population according to PLR value.
4. Our study population was small, and a larger sample size will be required for prospective clinical studies.
5. This study focused on in-hospital screening and adverse events among participants and lacked long-term follow-up results.

Introduction

Acute myocardial infarction (AMI) is one of the leading causes of death worldwide (1). Emergency coronary intervention (PPCI) is the first choice for AMI patients to restore blood flow. Studies have shown that early reperfusion can effectively reduce the myocardial infarct (MI) size and restore heart function (2). Although blood flow of the occluded vascular artery is restored (thrombolysis in myocardial infarction (TIMI) grade 3 after PPCI), many patients still have insufficient myocardial perfusion (3). This could result in severe myocardial ischaemia, malignant arrhythmia, haemodynamic deterioration and other adverse outcomes (4-7). The insufficient myocardial perfusion is mainly due to microvascular obstruction (MVO) (8). The main mechanism of microvascular obstruction is ischaemia-reperfusion (IR) injury to coronary arteries. This injury involves multiple pathophysiological factors

1
2
3
4 (calcium overload, oxidative stress, inflammation, and mitochondrial dysfunction)
5
6 and multiple players (cardiomyocytes, microvasculature, inflammatory cells, and
7
8 platelets), making it a complex system (9). Therefore, it is necessary to find the risk
9
10 factors that affect myocardial reperfusion.
11
12

13
14 Platelet activation plays a critical role in the formation of acute thrombosis of
15
16 coronary arteries (10). Increased platelet count is associated with the MI size in AMI
17
18 patients and can lead to adverse cardiovascular events (11). The inflammatory
19
20 response plays an important role in the formation of atherosclerotic plaques and
21
22 myocardial ischaemia-reperfusion injury. Studies have shown that decreased
23
24 lymphocyte count was associated with increased mortality in AMI patients (12-14).
25
26 Previous studies have found that PLR can be used as a predictor of long-term
27
28 mortality and is an independent risk factor for no reflow after PPCI and increased
29
30 mortality in hospital, and the increase in PLR is positively correlated with the 6-
31
32 month all-cause mortality in STEMI patients (15-18).
33
34
35
36
37
38
39

40
41 Studies have shown that the presence of MVO after PPCI as assessed by TIMI flow
42
43 post-PPCI and MBG have all strongly been linked with worse outcomes in AMI
44
45 patients (19-20). The index of microcirculatory resistance (IMR) is a parameter for
46
47 quantifying microcirculatory resistance. There are significant differences in the
48
49 microvascular blood flow between the left anterior descending branch (LAD) and left
50
51 circumflex branch (LCX), as well as the right coronary artery (RC) (21). Although
52
53 previous studies have investigated the relationship between PLR and AMI, they have
54
55 ignored the influence of myocardial ischaemic adaptation in different coronary
56
57
58
59
60

1
2
3
4 arteries on myocardial reperfusion. To avoid the influence of this variation on the
5
6 results, we only included AMI patients with proximal LAD blocking. Thus, this study
7
8 intends to explore the effects of PLR on myocardial reperfusion and adverse events in
9
10 AMI patients and to provide guidance for the improvement of reperfusion therapy.
11
12

13 14 **Material and Methods**

15 16 **Participants**

17
18 This study is a multiple-centre retrospective cohort study. A total of 445
19
20 consecutive AMI patients from two hospitals seen between January 2015 and
21
22 December 2017 were reviewed. We analysed the clinical and angiographic data of
23
24 consecutive patients diagnosed with acute myocardial infarction. The inclusion
25
26 criteria were as follows: 1. They were eligible for the diagnostic criteria of STEMI; 2.
27
28 There was ≤ 12 hours from the onset of symptoms to PPCI; 3. The results of
29
30 angiography confirmed that the infarcted blood vessel was the proximal left anterior
31
32 descending (LAD); and 4. Complete clinical data were collected. The exclusion
33
34 criteria were as follows: 1. Active infection; 2. History of systemic infectious diseases
35
36 in the previous two weeks; 3. Malignant tumour; 4. Hepatopathy; 5 Chronic
37
38 tuberculosis history; 6. History of heart failure; 7. History of PCI; 8. Long-term oral
39
40 antiplatelet or statin drugs. All patients received 300 mg of aspirin and 600 mg
41
42 clopidogrel or 180 mg of ticagrelor before PPCI. This study protocol was reviewed
43
44 and approved by the Institutional Review Board of the First Affiliated Hospital of
45
46 Xinjiang Medical University and conformed to the principles and guidelines of the
47
48 Declaration of Helsinki. All participants or their close relatives provided written
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 informed consent for participation before data collection.
5

6 **Clinical data collection**

7
8
9 Clinical data were collected from the medical records of hospitals by two
10
11 physicians independently. Basic information: hospital number, telephone number,
12
13 etc.; previous medical history and personal history: hypertension and grade, diabetes,
14
15 hyperlipidaemia, stroke history, prehospital medication history, and smoking history.
16
17 Venous blood samples were drawn before PPCI. Blood test parameters and other
18
19 measurements were determined by standard laboratory methods. Records of blood
20
21 routine before PPCI: biochemical measurements, myocardial enzymes, and BNP.
22
23 Cardiac ultrasound was done after PPCI. The TIMI and MBG grades of patients were
24
25 recorded by two interventional doctors in a blind manner. The number of diseased
26
27 blood vessels, sizes of the stents, number of clots, and use of tirofiban were
28
29 determined by operation records.
30
31
32
33
34
35
36
37

38 **Clinical definitions**

39
40 The study population was divided into tertiles according to the PLR values at
41
42 admission. High PLR (group 1, n=150) was defined as a value in the third tertile
43
44 (≥ 165.33) and low PLR (group 2, n=295) as a value in the lower two tertiles ($<$
45
46 165.33). Cardiovascular mortality was defined as unexplained sudden death, death
47
48 due to AMI, or malignant arrhythmia. Reinfarction was defined based on the universal
49
50 definition of MI guidelines. Non-lethal myocardial infarction was defined as type 1 or
51
52 type 2 myocardial infarction according to guidelines (22). Major adverse cardiac
53
54 events (MACEs) were defined as cardiovascular death, reinfarction, or target vessel
55
56
57
58
59
60

1
2
3
4 revascularization.

5
6 Insufficient myocardial perfusion was defined as a postoperative TIMI grade less
7
8
9 than 3 or a TIMI grade of 3 but with an MBG classification less than 2 (23).

10 11 **Statistical analysis**

12
13
14 All data were analysed by SPSS V 24.0 for Windows. Continuous variables are
15
16 presented as the mean \pm standard deviation. If two groups of quantitative data were
17
18 consistent with the normal distribution, then they were compared by the independent-
19
20 sample t test . If they did not fit the normal distribution, then they were compared by
21
22 Wilcoxon's rank test. Two groups of count data were compared by the chi-square test
23
24 or, if the frequency was lower than 5, Fisher's exact test. A backward stepwise
25
26 multivariate logistic regression analysis was performed to identify independent
27
28 predictors of insufficient myocardial perfusion. Statistical significance was defined as
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 $P < 0.05$.

37 38 **Patient and public involvement**

39
40
41 Participants were not involved in the study design, recruitment, implementation,
42
43 article writing, or data collection. Patients did not incur additional medical burden in
44
45 the study. The results of the study will be disseminated to all patients and medical
46
47 institutions through academic conferences, news reports and health publicity.

51 52 **Results**

53
54 The baseline characteristics of the two groups are presented in table 1. A total of
55
56 445 patients (136 from one medical centre, 309 from the other) were eligible. High-
57
58 PLR patients were admitted to hospital with a significantly higher Killip class than
59
60

low-PLR patients (86% vs. 74.6%, $P=0.006$). The left ventricular ejection fraction of patients in the high-PLR group was significantly lower than that in the low-PLR group ($34.8\% \pm 6.0$ vs. $37.4\% \pm 7.1$, $P=0.006$). Gender, hypertension, diabetes, history of stroke, smoking, hyperlipidaemia, and time from symptom onset to intervention were not significantly different between the two groups ($P > 0.05$).

Table 1. Baseline clinical characteristics of patients

	High PLR (n=150)	Low PLR (n=295)	<i>P</i> value
Age, years $\bar{x} \pm s$	62.2 \pm 14.1	59.5 \pm 12.2	0.117
Male, n(%)	93 (62%)	196 (66.4%)	0.335
Hypertension, n(%)	80 (53.3%)	160 (54.2%)	0.856
Diabetes, n(%)	33 (22%)	80 (27.1%)	0.241
Stroke, n(%)	13 (8.7%)	20 (6.8%)	0.473
Smoking, n(%)	57 (38%)	130 (44.1%)	0.220
Hyperlipidaemia, n(%)	6 (4%)	16 (5.4%)	0.513
Killip class \geq II, n(%)	129 (86%)	220 (74.6%)	0.006
Ejection fraction, $\bar{x} \pm s$	34.8 \pm 6.0	37.4 \pm 7.1	0.006
Symptom onset to intervention (hours)	7.00 \pm 4.83	7.15 \pm 4.80	0.608
≥ 6	66(44.0%)	131(44.4%)	0.935

The laboratory data of the two groups are presented in Table 2. The preoperative white blood cell count (WBC) (9.5 ± 4.1 vs. 9.0 ± 3.2 , $P=0.044$) and red cell distribution width (RDW) (13.6 ± 3.1 vs. 13.2 ± 2.3 , $P=0.026$) in the low-PLR group were significantly lower. The peak values of brain natriuretic peptide (BNP) (614 ± 610 pg/ml vs. 316 ± 429 pg/ml, $P < 0.001$) and alanine aminotransferase (ALT) (64.4 ± 84.4 U/L vs. 52.1 ± 60.0 U/L, $P=0.003$) was significantly higher than in the high-PLR group. There was no significant difference in neutrophil count, monocyte count, haemoglobin, creatinine, total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), C-reactive protein (CRP), peak cTnT, or peak

CK-MB.

Table 2. Comparison of laboratory results

	High PLR (n=150)	Low PLR (n=295)	P value
WBC×10 ⁹ /L (x±s)	9.5±4.1	9.0±3.2	0.044
Neutrophil×10 ⁹ /L (x±s)	8.1±6.8	6.5±6.2	0.171
Platelet×10 ⁹ /L (x±s)	264.2±85.9	203.5±74.6	0.006
Lymphocyte×10 ⁹ /L (x±s)	1.15±0.47	2.23±2.41	0.081
Monocyte×10 ⁹ /L (x±s)	0.5±0.3	1.0±4.6	0.167
Haemoglobin (g/L, x±s)	129.6±23.7	135.8±23.0	0.524
RDW (% , x±s)	13.6±3.1	13.2±2.3	0.026
ALT (U/L, x±s)	64.4±84.4	52.1±60.0	0.003
Creatinine (μmol/L, x±s)	76.3±30.8	78.4±36.3	0.336
Total cholesterol (μmol/L, x±s)	4.1±1.0	4.1±1.1	0.198
HDL-cholesterol (μmol/L, x±s)	1.1±0.3	1.0±0.5	0.446
LDL-cholesterol (μmol/L, x±s)	2.5±0.8	2.5±0.9	0.880
CRP (mg/L, x±s)	17.8±32.0	16.7±26.6	0.611
Peak cTnT (U/L, x±s)	5.7±4.0	4.9±3.8	0.236
Peak CK-MB (U/L, x±s)	242±382	226±335	0.498
BNP (pg/ml, x±s)	614±600	316±429	< 0.001

WBC: white blood cell count; RDW: red cell distribution width; ALT: alanine aminotransferase; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CRP: C-reactive protein; CK-MB: creatine kinase-myocardial band; BNP: brain natriuretic peptide

The angiographic and procedural characteristics of the two groups are presented in Table 3. In the high-PLR group, the average implanted stent diameter was significantly smaller (2.93±0.47 vs. 2.96±0.40, P=0.015), thrombus aspiration was higher (64% vs. 52%, P=0.015), and platelet count was higher (264.2±85.9 vs. 203.5±74.6, P=0.006). The patients in the high-PLR group had significantly lower postprocedural TIMI grade (17% vs. 10%, P=0.037) and MBG stage (11% to 4%, P=0.007) after PCI. In the high-PLR group, the incidence of insufficient myocardial

perfusion was significantly increased (23% vs. 13%, $P=0.003$). There was no significant difference in the number of diseased vessels, the number of stents used, the average implanted stent length, or the use of tirofiban. The MACEs in the high-PLR group were significantly more common (43% vs. 32%, $P=0.004$). There was no significant difference in non-lethal myocardial infarction, stroke, in-hospital mortality or ventricular tachycardia/ventricular fibrillation (Table 4).

Table 3. Angiographic and procedural characteristics of patients

	High PLR (n=150)	Low PLR (n=295)	<i>P</i> value
Number of diseased vessels			
1, n(%)	54 (36%)	103 (35%)	0.821
≥2, n(%)	96 (64%)	192 (65%)	
Number of stent use			
1, n(%)	66 (44%)	119 (40%)	0.459
≥2, n(%)	84 (56%)	176 (60%)	
Stent length, average (mm, $x\pm s$)	26.4±8.1	25.9±6.3	0.067
Stent diameter, average (mm, $x\pm s$)	2.93±0.47	2.96±0.40	0.015
Tirofiban use, n (%)	135 (90%)	271 (92%)	0.511
Thrombus aspiration, n (%)	96 (64%)	153 (52%)	0.015
Postprocedural TIMI grade			
0-2, n (%)	25(17%)	29(10%)	0.037
3, n (%)	125(83%)	266(90%)	
MBG grade			
0,1, n (%)	16(11%)	12(4%)	0.007
2,3, n (%)	134(89%)	283(96%)	
Insufficient myocardial reperfusion	35(23%)	37(13%)	0.003

TIMI: Thrombolysis in Myocardial Infarction; MBG: myocardial blush grade

Table 4. In-hospital cardiac events and complications

	High PLR (n=150)	Low PLR (n=295)	<i>P</i> value
MACEs	64 (43%)	95 (32%)	0.029

Non-lethal myocardial infarction, n (%)	6 (4%)	7 (2%)	0.335
Stroke, n (%)	11 (7%)	18 (6%)	0.619
In-hospital mortality, n (%)	4 (3%)	2 (1%)	0.186
Ventricular tachycardia/ventricular fibrillation, n (%)	42 (28%)	69 (23%)	0.288

MACEs: major adverse cardiac events (cardiovascular death, reinfarction, target vessel revascularization)

We performed univariate logistic regression analysis of factors affecting the sufficiency of myocardial perfusion, and the results showed that high BNP (OR 1.329, 95% CI 1.057 to 1.672 ($P = 0.015$)) and high PLR (OR 1.254, 95% CI 1.001 to 1.571 ($P = 0.051$)) contributed to the insufficient myocardial perfusion of PPCI patients. We included all factors to perform multivariate logistic regression analysis. We found that high PLR (OR 1.256, 95% CI 1.003 to 1.579 ($P = 0.056$)) and high BNP (OR 1.328, 95% CI 1.056 to 1.670 ($P = 0.015$)) were independent risk factors for insufficient myocardial perfusion (Table 5).

Table 5. The independent predictors of insufficient myocardial reperfusion

Variable	Univariate		Multivariate	
	OR (95% CI)	<i>P</i> value	OR (95% CI)	<i>P</i> value
Age	1.013 (0.983-1.033)	0.202	1.008 (0.988-1.028)	0.440
Male sex	1.018 (0.599-1.728)	0.948	1.009 (0.554-1.839)	0.975
Killip class \geq II	1.167 (0.620-2.198)	0.632	0.980 (0.460-2.086)	0.958
Ejection fraction	0.985 (0.948-1.023)	0.436	0.986 (0.947-1.027)	0.488
WBC	1.049 (0.983-1.119)	0.151	1.044 (0.977-1.116)	0.206
Platelet	1.002 (0.999-1.005)	0.037	1.000 (0.996-1.005)	0.872
Lymphocyte	0.766 (0.542-1.082)	0.130	0.906 (0.611-1.344)	0.624
RDW	1.016 (0.928-1.112)	0.734	1.008 (0.911-1.115)	0.878
ALT	0.999 (0.995-1.003)	0.576	0.991 (0.993-1.002)	0.268
Stent length	1.007 (0.971-1.044)	0.710	1.005 (0.969-1.042)	0.793
Stent diameter	1.168 (0.643-2.124)	0.610	1.071 (0.571-2.009)	0.831
Thrombus aspiration	1.123 (0.673-1.872)	0.657	1.046 (0.614-1.780)	0.869
BNP	1.329 (1.057-1.672)	0.015	1.328 (1.056-1.670)	0.015
PLR	1.254 (1.001-1.571)	0.051	1.256 (1.003-1.579)	0.056

WBC: white blood cell count; RDW: red cell distribution width; ALT: alanine aminotransferase; BNP: brain natriuretic peptide; PLR: platelet to lymphocyte ratio.

Discussion

In our study, after controlling for the effects of different coronary artery lesions on insufficient myocardial reperfusion, it was found that high PLR and BNP were independent risk factors for insufficient myocardial reperfusion after PPCI for AMI patients. Earlier studies have shown that high PLR is significantly correlated with MACEs, Killip grade, EF value, platelet count, RDW, length/diameter of stent implantation, and thrombus aspiration in AMI patients.

The pathophysiological mechanism of insufficient myocardial reperfusion is that microvascular blood flow is hindered by MVO (9,24). The aetiological mechanisms are that 1) platelet activation and adhesion, which increase cell death and aggregation, can affect myocardial flow (25); 2) increased endothelial permeability and subsequent recruitment of inflammatory cells into the site of infarction can lead to acute IR injury (26); 3) mitochondrial dysfunction caused by calcium overload and ROS accumulation can also lead to IR injury (27). PLR as an index contains information on platelet and lymphocyte counts in patients with AMI. It is more significant in predicting insufficient myocardial reperfusion after PPCI in AMI patients than platelet or lymphocyte count. Platelets play a key role in the pathogenesis of AMI through the formation of platelet-fibrin complexes (10). Increasing platelet count has been associated with the occurrence of AMI (28). Activating platelets adhere to vascular endothelial cells and produce inflammatory cytokines, leading to mononuclear cell adhesion and migration, accelerating the progression of atherosclerotic plaques. These activating adhesion molecules and chemokines promote the activation of white blood cells and produce

1
2
3
4 reactive oxygen species and matrix metalloproteinases, causing plaque instability in
5
6 atherosclerotic plaques (29). Gary et al. found that increasing platelet volume can
7
8 change blood viscosity and promote inflammation (30). Temiz et al. found that
9
10 increasing platelet activity was associated with a high incidence of cardiovascular
11
12 events in hospital (31). These studies indicated that the increase in platelet count was
13
14 significantly correlated with the occurrence of AMI and poor prognosis.
15
16
17

18
19 During the pathogenetic process of AMI, lymphocytes enter the ischaemia-
20
21 reperfusion-injured myocardial tissue and secrete IL-10 to inhibit the inflammatory
22
23 response. The lymphocytes also secrete TF and mmp-1 to promote the coagulation
24
25 reaction (29). Studies have shown a correlation between decreased lymphocyte count
26
27 and increased frequency of cardiovascular events in patients with AMI (12,32). A
28
29 decrease in lymphocyte count caused by stress can increase the incidence of death in
30
31 AMI patients (33). Therefore, PLR may become a new indicator of thrombus
32
33 formation, inflammatory state, and short-term and long-term adverse outcomes of
34
35 patients with AMI.
36
37
38
39
40
41
42

43 Based on the TIMI class after PCI, Abdulkadir et al. divided acute STEMI patients
44
45 into two groups: no-reflow and reflow. An analysis of routine blood examination
46
47 before PCI and myocardial reperfusion showed that increasing the PLR value was an
48
49 independent risk factor for the prediction of no-reflow in acute STEMI patients (34).
50
51 Burak et al. used ROC curve analysis to show that a PLR>137 predicted adverse
52
53 events for patients who had undergone PPCI, with a specificity of 67% and a
54
55 sensitivity of 63% (35). Alparslan et al. found that PLR was significantly associated
56
57
58
59
60

1
2
3
4 with the severity and complexity of coronary atherosclerosis in ACS patients who
5
6 underwent PPCI. A higher PLR value was an independent predictor of an
7
8 intermediate to high SXscore (17). Preintervention PLR was a strong and independent
9
10 predictor of slow flow/no-reflow after PPCI in patients with acute STEMI (36). Murat
11
12 et al. found that higher PLR was associated with an increased risk for in-hospital
13
14 adverse outcomes and 6-month all-cause mortality with STEMI after PPCI (18). PLR
15
16 should be incorporated into the clinical practice of risk stratification for patients
17
18 admitted with STEMI who undergo primary PCI.
19
20
21
22
23

24
25 Our study found that high BNP was an independent risk factor for insufficient
26
27 myocardial reperfusion after PPCI in AMI patients. BNP is a quantitative marker of
28
29 heart failure that is significantly correlated with left ventricular systolic function (37).
30
31 During the process of hypoxia, oedematosis, and necrosis at the myocardial infarction
32
33 site, cardiomyocytes can produce BNP through the transcription of the NPPB gene in
34
35 the endoplasmic reticulum (38). When occlusion of the proximal LAD causes hypoxia
36
37 and oedema of myocardial cells, BNP will be secreted in large quantities. Elevated
38
39 BNP leads to plasma concentrations of angiotensin II (Ang II) and endothelin-1 (ET-
40
41 1) by activating the renin angiotensin system (RAS) (39). This will further aggravate
42
43 the reperfusion of ischaemic myocardium at the infarct site. BNP has been shown to
44
45 be an independent risk factor for ischaemia-reperfusion injury in ST-segment
46
47 elevation AMI patients (40). Studies have shown that the increased secretion of BNP
48
49 during myocardial ischaemia is mainly regulated by the PI3K/Akt/p70s6k signalling
50
51 pathway, which has a protective effect on the myocardium (41). This change is an
52
53
54
55
56
57
58
59
60

1
2
3
4 adaptation of myocardial cells to ischaemia. Therefore, the BNP level can reflect the
5
6 severity of myocardial ischaemia, which is strongly related to insufficient myocardial
7
8 reperfusion. This study also found that thrombus aspiration was associated with
9
10 insufficient myocardial reperfusion in patients with AMI. At present, the role of
11
12 thrombus aspiration in PPCI patients is still controversial (42,43). The TAPAS study
13
14 showed that thrombus aspiration in PPCI patients did not reduce the total mortality at
15
16 30 days or 1 year (44). The TOTAL study showed that the main endpoints followed
17
18 up for 180 days (6.9% vs. 7.0%). $P=0.86$) and 1 year (7.8% vs. 7.8%; $P=0.991$) were
19
20 not significantly different between the thrombus aspiration group and non-thrombus
21
22 aspiration group (45). In addition, a study showed that thrombus aspiration did not
23
24 improve myocardial reperfusion in patients with long-term ischaemia, small infarction
25
26 area and light thrombosis (46). Hoole et al. observed changes in microvascular
27
28 resistance (IMR) during PPCI and found that patients with relatively light thrombosis
29
30 were prone to distal embolization after thrombus aspiration, which would lead to
31
32 microcirculation injury (47).

33
34
35
36
37
38
39
40
41
42
43 Limitations of this study: 1) The sample size of this study was small, and
44
45 prospective clinical studies with larger samples are needed to confirm the findings. 2)
46
47 This study did not evaluate the decline in the ECG ST segment after emergency PCI,
48
49 but a former study showed that the ST fallback was consistent with the MBG grading
50
51 results. 3) Long-term follow-up was not conducted, and further study is needed to
52
53 evaluate the long-term prognosis of patients with AMI.
54
55
56

57 58 59 60 **Conclusion**

1
2
3
4 In conclusion, our study showed that high PLR and BNP on hospital admission could
5
6 be used as independent risk factors for predicting insufficient myocardial reperfusion
7
8 after PPCI in AMI patients with proximal LAD occlusion. High PLR is associated with
9
10 higher MACE incidence during hospitalization. PLR and BNP are convenient and
11
12 inexpensive to detect in clinical practice. Clinicians can grade the risk of insufficient
13
14 myocardial reperfusion in AMI patients according to the PLR value.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank our colleagues for their help. We also thank all the patients for their support.

Funding

This work was supported by NSFC grant number 2017E0269.

Conflict of any competing interests

None declared.

Contributor ship statement

Ailifeire Maimaiti and Li Yang contributed equally to this work. Ailifeire Maimaiti and Yong-Tao Wang were responsible for the statistical analysis and write this paper. Li Yang and Xiang Yang provided the database. Xiao-Mei Li and Yi-Ning Yang critically revised the paper for important intellectual content. Yi-Tong Ma was accountable for all aspects of the work and fund collection.

Data sharing statement

The data sets generated and analysed during the current study are available from the corresponding author upon reasonable request.

References

1. Reed Grant W, Rossi Jeffrey E, Cannon Christopher P, Acute myocardial infarction. [J] .Lancet, 2017, 389: 197-210.
2. Tra Joppe, van der Wulp Ineke, de Bruijne Martine C et al. Exploring the treatment delay in the care of patients with ST-elevation myocardial infarction undergoing acute percutaneous coronary intervention: a cross-sectional study. [J] .BMC Health Serv Res, 2015, 15: 340.
3. Ndrepepa Gjin, Tiroch Klaus, Fusaro Massimiliano et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. [J] .J. Am. Coll. Cardiol., 2010, 55(21): 2383-9.
4. Haeck Joost D E, Relationship between myocardial reperfusion, infarct size, and mortality. [J] .JACC Cardiovasc Interv, 2013, 6: 1328.
5. Stone Gregg W, Peterson Michael A, Lansky Alexandra J et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. [J] .J. Am. Coll. Cardiol., 2002, 39: 591-7.
6. Gibson C M, Cannon C P, Murphy S A et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. [J] .Circulation, 2000, 101: 125-30.
7. Hoffmann Rainer, Haager Philipp, Arning Jan et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. [J] .Am. J. Cardiol., 2003, 92: 1015-9.
8. Krug A, Du Mesnil de Rochemont , Korb G, Blood supply of the myocardium after

- 1
2
3
4 temporary coronary occlusion.[J] .Circ. Res., 1966, 19: 57-62.
5
6
7 9. Hausenloy Derek J,Botker Hans Erik,Engstrom Thomas et al. Targeting reperfusion
8
9 injury in patients with ST-segment elevation myocardial infarction: trials and
10
11 tribulations.[J] .Eur. Heart J., 2017, 38: 935-941.
12
13
14 10. Davì Giovanni,Patrono Carlo,Platelet activation and atherothrombosis.[J] .N. Engl. J.
15
16 Med., 2007, 357: 2482-94.
17
18
19 11. Gibson C Michael,Karha Juhana,Murphy Sabina A et al. Early and long-term clinical
20
21 outcomes associated with reinfarction following fibrinolytic administration in the
22
23 Thrombolysis in Myocardial Infarction trials.[J] .J. Am. Coll. Cardiol., 2003, 42: 7-16.
24
25
26
27 12. Horne Benjamin D,Anderson Jeffrey L,John Jerry M et al. Which white blood cell
28
29 subtypes predict increased cardiovascular risk?[J] .J. Am. Coll. Cardiol., 2005, 45: 1638-
30
31 43.
32
33
34
35 13. Guasti Luigina,Dentali Francesco,Castiglioni Luana et al. Neutrophils and clinical
36
37 outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A
38
39 systematic review on more than 34,000 subjects.[J] .Thromb. Haemost., 2011, 106(4):
40
41 591-9.
42
43
44
45 14. Bian Chang,Wu Yihua,Shi Yu et al. Predictive value of the relative lymphocyte count in
46
47 coronary heart disease.[J] .Heart Vessels, 2010, 25: 469-73.
48
49
50
51 15. Li Wenzhang,Liu Qianqian,Tang Yin. Platelet to lymphocyte ratio in the prediction of
52
53 adverse outcomes after acute coronary syndrome: a meta-analysis.[J] .Sci Rep, 2017, 7:
54
55 40426.
56
57
58 16. Azab Basem,Shah Neeraj,Akerman Meredith et al. Value of platelet/lymphocyte ratio as
59
60

- 1
2
3
4 a predictor of all-cause mortality after non-ST-elevation myocardial infarction.[J] .J.
5
6 Thromb. Thrombolysis, 2012, 34: 326-34.
7
8
9 17. Kurtul Alparslan,Murat Sani Namik,Yarlioglues Mikail et al. Association of platelet-to-
10
11 lymphocyte ratio with severity and complexity of coronary artery disease in patients with
12
13 acute coronary syndromes.[J] .Am. J. Cardiol., 2014, 114: 972-8.
14
15
16
17 18. Ugur Murat,Gul Mehmet,Bozbay Mehmet et al. The relationship between platelet to
18
19 lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction
20
21 underwent primary coronary intervention.[J] .Blood Coagul. Fibrinolysis, 2014, 25: 806-
22
23 11.
24
25
26
27 19. Morishima I,Sone T,Okumura K et al. Angiographic no-reflow phenomenon as a
28
29 predictor of adverse long-term outcome in patients treated with percutaneous
30
31 transluminal coronary angioplasty for first acute myocardial infarction.[J] .J. Am. Coll.
32
33 Cardiol., 2000, 36: 1202-9.
34
35
36
37 20. Sorajja Paul,Gersh Bernard J,Costantini Costantino et al. Combined prognostic utility of
38
39 ST-segment recovery and myocardial blush after primary percutaneous coronary
40
41 intervention in acute myocardial infarction.[J] .Eur. Heart J., 2005, 26: 667-74.
42
43
44
45 21. Lee Joo Myung,Layland Jamie,Jung Ji-Hyun et al. Integrated physiologic assessment of
46
47 ischemic heart disease in real-world practice using index of microcirculatory resistance
48
49 and fractional flow reserve: insights from the International Index of Microcirculatory
50
51 Resistance Registry.[J] .Circ Cardiovasc Interv, 2015, 8: e002857.
52
53
54
55 22. Thygesen Kristian,Alpert Joseph S,White Harvey D et al. Universal definition of
56
57 myocardial infarction.[J] .J. Am. Coll. Cardiol., 2007, 50(22): 2173-95.
58
59
60

- 1
2
3
4 23. Niccoli Giampaolo,Burzotta Francesco,Galiuto Leonarda et al. Myocardial no-reflow in
5
6 humans.[J] .J. Am. Coll. Cardiol., 2009, 54: 281-92.
7
8
9 24. Niccoli Giampaolo,Scalone Giancarla,Lerman Amir et al. Coronary microvascular
10
11 obstruction in acute myocardial infarction.[J] .Eur. Heart J., 2016, 37: 1024-33.
12
13
14 25. De Waha Suzanne,Patel Manesh R,Granger Christopher B et al. Relationship between
15
16 microvascular obstruction and adverse events following primary percutaneous coronary
17
18 intervention for ST-segment elevation myocardial infarction: an individual patient data
19
20 pooled analysis from seven randomized trials.[J] .Eur. Heart J., 2017, 38(47): 3502-3510.
21
22
23 26. Aurigemma Cristina,Scalone Giancarla,Tomai Fabrizio et al. Persistent enhanced platelet
24
25 activation in patients with acute myocardial infarction and coronary microvascular
26
27 obstruction: clinical implications.[J] .Thromb. Haemost., 2014, 111: 122-30.
28
29
30 27. Hausenloy Derek J,Chilian William,Crea Filippo et al. The coronary circulation in acute
31
32 myocardial ischaemia/reperfusion injury - a target for cardioprotection.[J] .Cardiovasc.
33
34 Res., 2018, undefined: undefined.
35
36
37 28. Javadov Sabzali,Jang Sehwan,Parodi-Rullán Rebecca et al. Mitochondrial permeability
38
39 transition in cardiac ischemia-reperfusion: whether cyclophilin D is a viable target for
40
41 cardioprotection?[J] .Cell. Mol. Life Sci., 2017, 74: 2795-2813.
42
43
44 29. Amraotkar Alok Ravindra,Song David Day,Otero Diana et al. Platelet Count and Mean
45
46 Platelet Volume at the Time of and After Acute Myocardial Infarction.[J] .Clin. Appl.
47
48 Thromb. Hemost., 2017, 23(8): 1052-1059.
49
50
51 30. Lindemann S,Krämer B,Seizer P et al. Platelets, inflammation and atherosclerosis.[J] .J.
52
53 Thromb. Haemost., 2007, null: 203-11.
54
55
56
57
58
59
60

- 1
2
3
4 31. Gary Thomas,Pichler Martin,Belaj Klara et al. Platelet-to-lymphocyte ratio: a novel
5
6 marker for critical limb ischemia in peripheral arterial occlusive disease
7
8
9 patients.[J] .PLoS ONE, 2013, 8: e67688.
10
- 11 32. Temiz Ahmet,Gazi Emine,Güngör Ömer et al. Platelet/lymphocyte ratio and risk of in-
12
13 hospital mortality in patients with ST-elevated myocardial infarction.[J] .Med. Sci.
14
15 Monit., 2014, 20: 660-5.
16
17
- 18 33. Frangogiannis Nikolaos G,Smith C Wayne,Entman Mark L,The inflammatory response
19
20 in myocardial infarction.[J] .Cardiovasc. Res., 2002, 53: 31-47.
21
22
- 23 34. Ommen S R,Gibbons R J,Hodge D O et al. Usefulness of the lymphocyte concentration
24
25 as a prognostic marker in coronary artery disease.[J] .Am. J. Cardiol., 1997, 79: 812-4.
26
27
- 28 35. Yildiz Abdulkadir,Yuksel Murat,Oylumlu Mustafa et al. The Utility of the Platelet-
29
30 Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation
31
32 Myocardial Infarction.[J] .Clin. Appl. Thromb. Hemost., 2015, 21(3): 223-8.
33
34
- 35 36. Ayça Burak,Akin Fatih,Okuyan Ertuğrul. Platelet to lymphocyte ratio as a prognostic
36
37 marker in primary percutaneous coronary intervention.[J] .Platelets, 2015, 26(8): 816.
38
39
- 40 37. Akboga Mehmet Kadri,Canpolat Ugur,Balci Kevser Gulcihan et al. Increased Platelet to
41
42 Lymphocyte Ratio is Related to Slow Coronary Flow.[J] .Angiology, 2016, 67(1): 21-6.
43
44
- 45 38. Abassi Zaid,Karram Tony,Allaham Samer et al. Implications of the natriuretic
46
47 peptide system in the pathogenesis of heart failure: diagnostic and therapeutic
48
49 importance.[J] .Pharmacol. Ther., 2004, 102: 223-41.
50
51
- 52 39. Hama N,Itoh H,Shirakami G et al. Rapid ventricular induction of brain natriuretic
53
54 peptide gene expression in experimental acute myocardial
55
56
57
58
59
60

- 1
2
3
4 infarction.[J] .Circulation, 1995, 92: 1558-64.
5
6
7 40. Luodonpää M,Vuolteenaho O,Eskelinen S et al. Effects of adrenomedullin on
8
9 hypertrophic responses induced by angiotensin II, endothelin-1 and
10
11 phenylephrine.[J] .Peptides, 2001, 22: 1859-66.
12
13
14 41. Arakawa Kentaro, Himeno Hideo, Kirigaya Jin et al. B-type natriuretic peptide as
15
16 a predictor of ischemia/reperfusion injury immediately after myocardial
17
18 reperfusion in patients with ST-segment elevation acute myocardial
19
20 infarction.[J] .Eur Heart J Acute Cardiovasc Care, 2016, 5: 62-70.
21
22
23 42. Mahmoud Karim D,Zijlstra Felix. Thrombus aspiration in acute myocardial
24
25 infarction.[J] .Nat Rev Cardiol, 2016, 13(7): 418-28.
26
27
28 43. Jolly Sanjit S,James Stefan,Džavík Vladimír et al. Thrombus Aspiration in ST-Segment-
29
30 Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy
31
32 Trialists Collaboration.[J] .Circulation, 2017, 135(2): 143-152.
33
34
35 44. Svilaas Tone,Vlaar Pieter J,van der Horst Iwan C et al. Thrombus aspiration during
36
37 primary percutaneous coronary intervention.[J] .N. Engl. J. Med., 2008, 358(6): 557-67.
38
39
40 45. Jolly Sanjit S,Cairns John A,Yusuf Salim et al. Outcomes after thrombus aspiration for
41
42 ST elevation myocardial infarction: 1-year follow-up of the prospective randomised
43
44 TOTAL trial.[J] .Lancet, 2016, 387(10014): 127-35.
45
46
47 46. Vandermolen Sebastian,Marciniak Maciej,Byrne Jonathan et al. Thrombus aspiration in
48
49 acute myocardial infarction: concepts, clinical trials, and current guidelines.[J] .Coron.
50
51 Artery Dis., 2016, 27: 233-43.
52
53
54 47. Hoole Stephen P,Jaworski Catherine,Brown Adam J et al. Serial assessment of the index
55
56
57
58
59
60

1
2
3
4 of microcirculatory resistance during primary percutaneous coronary intervention
5
6 comparing manual aspiration catheter thrombectomy with balloon angioplasty (IMPACT
7
8
9 study): a randomised controlled pilot study.[J] .Open Heart, 2015, 2: e000238.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE Statement

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2-P3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4-P5
Objectives	3	State specific objectives, including any prespecified hypotheses	P5
Methods			
Study design	4	Present key elements of study design early in the paper	P5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P5-P6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P5
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
Variables	7	(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	P6
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
		Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P6-P7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P6
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	P6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P6-P7
		(a) Describe all statistical methods, including those used to control for confounding	P7
		(b) Describe any methods used to examine subgroups and interactions	P7
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	
Statistical methods	12	<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	P6
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	

Section/Topic	Item No	Recommendation	Reported on Page No
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P7
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P8-P9
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	P10
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P6
		(b) Report category boundaries when continuous variables were categorized	P11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	P11-P12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P12-P15
Generalisability	21	Discuss the generalisability (external validity) of the study results	P15
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.